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Examining the Roles of GABAA Receptor Subtypes in Anxiety and Anxiolysis:
Focusing on the Basolateral Amygdala
Abstract
The investigation of the differential roles GABAA receptor (GABAAR) subtypes play in mediating various
behaviors such as fear and anxiety was an intriguing research topic over the past decade. At present,
most evidence suggests that benzodiazepine (BZ)-induced anxiolysis is primarily mediated by GABAARs
containing the α2-subunit (α2-subtype). However, there is conflicting evidence as to whether α1- and
α3-subtypes might also be involved in BZ-induced anxiolysis. In an attempt to further discern the role
played by different α-subtype GABAARs in BZ-induced anxiolysis both systemically and within the
basolateral amygdala (BLA), a brain region crucial for anxiety-like behaviors, we examined the anxiolyticlike effects, as measured by elevated-plus maze test (EPM), of several subtype selective and nonselective GABAAR positive allosteric modulators (PAMs) both in wild type mice and in mutant mice that
express BZ-insensitive GABAARs of specific α-subtypes.
In our experiments, systemic injections of the α1-selective PAM zolpidem in WT mice produced slight
anxiolytic-like effects with a narrow therapeutic window that overlapped with prominent motor-inhibiting
effects. Systemic injection of the α3-selective PAM TP003 produced marked anxiolytic-like effects in WT
mice that were accompanied by motor-stimulating effects. Systemic injection of the α2-, α3-, and
α5-selective PAM L-838417 elicited significant anxiolytic-like effects in WT, and the effects were
weakened in the α3(H126R) mice. Similarly, anxiolytic-like effects were observed when these selective
PAMs were administered via microinjection into the BLA; however, these local injections did not
significantly affect motor activity at the doses tested. In the experiment examining systemic injections of
the non-selective BZ chlordiazepoxide (CDP), we found that CDP induced robust anxiolytic-like effects in
both male and female WT mice. These effects were potentiated in female α1(H101R) mice, and were
reduced in α2(H101R) mice of both sexes, as well as male α3(H126R) mice. Interestingly, intra-BLA
microinjection of CDP produced few effects in WT, α1(H101R), or α2(H101R) mice, but showed some
anxiolytic-like effects in α3(H126R) mice.
Taken together, our results suggests (i) all three (α1-, α2-, and α3-) GABAAR subtypes are involved in BZinduced anxiolysis, but subtle differences do exist; (ii) augmentation of the α1-subtype GABAARs exerts
anxiolytic-like effects; however, the therapeutic window is narrow; (iii) augmentation of the α2-, α3-, (and
α5-) subtype GABAARs exerts anxiolytic-like effects and motor-stimulating effects, and these effects are
weakened in α3(H126R) mice at doses tested, (iv) augmentation of the α3-subtype GABAARs exerts
anxiolytic-like effects, accompanied by motor-stimulating effects; (v) BLA is an important brain region that
is sufficient to mediate the anxiolytic-like effects, but not the motor-stimulating or inhibiting effects of
subtype selective GABAAR PAMs; and (vi) intra-BLA microinjection of CDP yielded an inconclusive
behavioral outcome, possibly due to the complex GABAergic intra-amygdaloidal microcircuitries which
might antagonize each other when multiple subtypes of GABAARs are simultaneously modulated by BZs.
Taken together, our results provide novel evidence that may benefit the current development of subtype
selective drugs for treating clinical anxiety disorders.
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ABSTRACT
The investigation of the differential roles GABAA receptor (GABAAR) subtypes
play in mediating various behaviors such as fear and anxiety was an intriguing research
topic over the past decade. At present, most evidence suggests that benzodiazepine (BZ)induced anxiolysis is primarily mediated by GABAARs containing the α2-subunit (α2subtype). However, there is conflicting evidence as to whether α1- and α3-subtypes might
also be involved in BZ-induced anxiolysis. In an attempt to further discern the role
played by different α-subtype GABAARs in BZ-induced anxiolysis both systemically and
within the basolateral amygdala (BLA), a brain region crucial for anxiety-like behaviors,
we examined the anxiolytic-like effects, as measured by elevated-plus maze test (EPM),
of several subtype selective and non-selective GABAAR positive allosteric modulators
(PAMs) both in wild type mice and in mutant mice that express BZ-insensitive
GABAARs of specific α-subtypes.
In our experiments, systemic injections of the α1-selective PAM zolpidem in WT
mice produced slight anxiolytic-like effects with a narrow therapeutic window that
overlapped with prominent motor-inhibiting effects. Systemic injection of the α3selective PAM TP003 produced marked anxiolytic-like effects in WT mice that were
accompanied by motor-stimulating effects. Systemic injection of the α2-, α3-, and α5selective PAM L-838417 elicited significant anxiolytic-like effects in WT, and the effects
were weakened in the α3(H126R) mice. Similarly, anxiolytic-like effects were observed
when these selective PAMs were administered via microinjection into the BLA; however,
these local injections did not significantly affect motor activity at the doses tested. In the
experiment examining systemic injections of the non-selective BZ chlordiazepoxide
(CDP), we found that CDP induced robust anxiolytic-like effects in both male and female
WT mice. These effects were potentiated in female α1(H101R) mice, and were reduced
in α2(H101R) mice of both sexes, as well as male α3(H126R) mice. Interestingly, intraBLA microinjection of CDP produced few effects in WT, α1(H101R), or α2(H101R)
mice, but showed some anxiolytic-like effects in α3(H126R) mice.
Taken together, our results suggests (i) all three (α1-, α2-, and α3-) GABAAR
subtypes are involved in BZ-induced anxiolysis, but subtle differences do exist; (ii)
augmentation of the α1-subtype GABAARs exerts anxiolytic-like effects; however, the
therapeutic window is narrow; (iii) augmentation of the α2-, α3-, (and α5-) subtype
GABAARs exerts anxiolytic-like effects and motor-stimulating effects, and these effects
are weakened in α3(H126R) mice at doses tested, (iv) augmentation of the α3-subtype
GABAARs exerts anxiolytic-like effects, accompanied by motor-stimulating effects; (v)
BLA is an important brain region that is sufficient to mediate the anxiolytic-like effects,
but not the motor-stimulating or inhibiting effects of subtype selective GABAAR PAMs;
and (vi) intra-BLA microinjection of CDP yielded an inconclusive behavioral outcome,
possibly due to the complex GABAergic intra-amygdaloidal microcircuitries which
might antagonize each other when multiple subtypes of GABAARs are simultaneously
modulated by BZs. Taken together, our results provide novel evidence that may benefit
the current development of subtype selective drugs for treating clinical anxiety disorders.
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CHAPTER 1.

INTRODUCTION

Background
The neurotransmitter gamma-aminobutyric acid (GABA), initially identified in
the brain circa 1950, is an key substance in mediating inhibitory neuronal functions
(Curtis, Duggan, Felix, & Johnston, 1970; Enna, 2011; Roberts, 1974; Roberts &
Frankel, 1950). There are three subcategories of GABA receptors, namely type A
(ionotropic), type B (metabotropic), and a third type, sometimes referred to as type C
(ionotropic) (Barnard et al., 1998). GABA type A receptors (GABAARs) are ligand-gated
ion channels that mediate chloride (anion) currents which, under normal physiological
conditions in adults, inhibits the neuron; although they might also mediate excitatory
transmission especially during early development (Barnard et al., 1998; Cherubini,
Gaiarsa, & Ben-Ari, 1991). GABAARs are pentameric receptors composed of unique
combinations of receptor subunits, including, but limited to, α, β, γ, or δ subunits (Olsen
& Sieghart, 2009; E. Sigel & Steinmann, 2012). Among them, α1β2γ2, α2β3γ2, and
α3β3γ2 are by far the highest expressed BZ-sensitive subunit compositions in the brain
(Whiting, 2003). The physiological response of GABAARs can be modulated by various
substrates that bind to different binding sites on the receptor, such as benzodiazepines
(BZs), ethanol, barbiturates, and neurosteroids (Olsen, 2015). GABAARs containing a α1, α2-, α3-, or α5-subunit positioned adjacent to the γ-subunit form a “BZ-site” that binds
BZ-like ligands, which can modulate the activity of GABAARs (Möhler, Crestani, &
Rudolph, 2001; Erwin Sigel, 2002). These receptors are often referred by which αsubunits they contain in adjacent to the γ-subunit, e.g., α1-, α2-, α3-, or α5-subtype
GABAARs. Positive modulation of GABAARs by BZs are known to mediate a plethora of
pharmacological and behavioral effects, such as anxiolysis (reduction of anxiety),
myorelaxation, sedation, amnesia, and seizure inhibition (Rudolph & Knoflach, 2011).
Among them, the anxiolytic-like effects of the positive allosteric modulators (PAMs) of
the BZ-site are of high significance in both clinical treatment of anxiety disorders and in
basic neuroscience research (Atack, 2010a; Kalat, 2007; T. A. Smith, 2001).
During the last two decades, considerable evidence has revealed similarities and
differences in the regional distribution and physiological functions of distinct GABAAR
subtypes (Rudolph & Knoflach, 2011). At present, several studies have revealed that the
α2-subtype GABAARs play a predominant role in BZ-induced anxiolysis (Low et al.,
2000; K. S. Smith, Engin, Meloni, & Rudolph, 2012). However, past studies have also
revealed conflicting results concerning the involvement of α1- and α3-subtype GABAARs
in anxiety, and have yet to distinguish the differential contribution of these subtypes. For
example, past evidence suggested that selective antagonism of the α1-subtype GABAAR
abolished the anxiolytic-like effects of systemic BZ treatment, supporting the
involvement of α1-subtype in BZ-induced anxiolysis (Belzung, Le Guisquet, & Griebel,
2000). Other studies using BZ-site point mutant mice that rendered them insensitive to
BZs, [α1(H101R), α2(H101R), and α3(H126R)], indicated the anxiolytic-like effects of
systemic BZ treatment are largely mediated by α2- rather than α1- or α3-subtype (Low et
al., 2000; K. S. Smith et al., 2012). Still, other independent studies found that systemic
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injection of the α3-selective PAM TP003 produced anxiolytic-like effects while systemic
administration of the α3-selective inverse-agonist Alpha3IA caused an anxiogenic-like
behavioral profile, supporting the possibility that α3-subtype also mediate BZ-induced
anxiolysis (Atack et al., 2005; Dias et al., 2005).
BZ-sensitive GABAARs are located in a number of brain regions known to play
roles in mediating behaviors indicative of anxiety, including the hippocampus, amygdala,
and bed nucleus of stria terminalis (Pirker, Schwarzer, Wieselthaler, Sieghart, & Sperk,
2000). Among them, the basolateral amygdala (BLA) is a particularly crucial brain region
involved in the control of anxiety and fear-related behaviors, and is densely populated
with BZ-sensitive GABAARs (M. Davis, 2000; File, 2000; LeDoux, 2000; Pirker et al.,
2000). It receives various sensory inputs and sends processed information to the central
amygdala (CeA), which is a main output nucleus controlling the downstream brain
regions that contribute to fear/anxiety responses (Janak & Tye, 2015; Lee, Kim, Kwon,
Lee, & Kim, 2013; Sah, Faber, Lopez De Armentia, & Power, 2003). Animal studies
showed that non-selective BZs produce anxiolytic-like effects when injected directly into
the BLA (McNamara & Skeleton, 1993; Menard & Treit, 1999; Pesold & Treit, 1995).
However, it is currently unclear whether these anxiolytic-like effects are mediated by the
action of BZs on particular α1-, α2- or α3-subtypes, or whether all subtypes act
synergistically to reduce anxiety.
In this study, we utilized both the point mutant mice and the subtype selective
GABAAR PAMs to investigate the differential roles of α1-, α2- and α3-subtypes in BZinduced anxiolysis after systemic injections. Further, we locally delivered the drugs to the
BLA to test whether BLA is a crucial brain area mediating the anxiolytic-like effects
found in global positive modulation of GABAAR by systemic injection. Our overall goal
is to assess and discern the differential contributions of α1-, α2- and α3-subtypes in
mediating BZ-induced anxiolysis, both systemically and within the BLA.
Clinical Significance
The acute use of classic non-selective BZs is effective in reducing anxiety in
humans. However, long-term use of BZs as an anxiolytic treatment can result in the
development of tolerance and dependence, among many other side effects (Stevens &
Pollack, 2005). Some evidence suggests that α1-subtype GABAARs mediate the
undesirable addictive properties of BZs (Rudolph & Knoflach, 2011; Tan et al., 2010). A
α1-subtype selective GABAAR PAM, zolpidem, also causes motor-impairing and
amnesic side effects in animal studies (Cope et al., 2004; Zanin et al., 2013), further
reviewed in (Fitzgerald, Wright, & Heldt, 2014). Thus, developing subtype selective
anxiolytics that have little affinity or efficacy to α1-subtype is promising (Atack, 2005).
In addition to BZs, selective serotonin reuptake inhibitors (SSRIs) that inhibit
serotonin reuptake and augment synaptic serotonin levels are also effective in reducing
anxiety; however, anxiolytic-like effects only develop following chronic, but not acute
treatment. In fact, acute SSRI treatment actually increases fear and anxiety responses in
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both human as well as in laboratory animals (Burghardt, Sullivan, McEwen, Gorman, &
LeDoux, 2004; Grillon, Levenson, & Pine, 2007; Pettersson, Naslund, Nilsson, Eriksson,
& Hagsater, 2015). The acute anxiogenic profile makes the usage of SSRI
disadvantageous in cases where anxiety symptoms need to be managed acutely
(Burghardt et al., 2004). Taken together, although classic non-selective BZs are suitable
for acute treatment of anxiety disorders, their tolerance properties and side effects render
them far from ideal for chronic anxiety management. Conversely, although SSRIs are
effective in chronic treatment settings, they are disadvantageous for situations where
anxiety symptoms needs to be managed acutely. This makes the development of novel
subtypes-selective GABAAR PAMs that retain the efficacy in anxiolysis but with their
side effects minimized a promising venue for improving the existing pharmaceutical
treatment options for anxiety disorders (Rudolph & Knoflach, 2011).
The purpose of the present study is to differentiate between the contributions of α1-, α2and α3-subtype GABAARs to BZ-induced anxiolysis. Our work will clarify not only the
general involvement of α-subtypes in BZ-induced anxiolysis but also reveal whether
positive modulations of different α-subtypes in the BLA participate in the induction of
anxiolysis. Our results may provide important evidence useful for the development of
novel subtype selective drugs for the treatment of clinical anxiety disorders.
Overview of Experimental Design
Systemic Injection of Selective GABAAR PAMs
We examined the presence (or absence) of anxiolytic-like effects elicited by
systemic administration of selective PAMs of α1-, α2- and/or α3-subtype GABAARs. To
achieve this, we assessed the anxiety-like behaviors using the EPM after selective
positive modulation of α1-, α2-, and/or α3-subtypes pharmacologically via systemic
injection of the following compounds: (i) Zolpidem, a α1-selective GABAAR PAM; (ii)
TP003, a α3-selective GABAAR PAM; (iii) L-838417, a partial PAM for the α2-, α3-,
and α5-subtypes (McKernan et al., 2000), was administered to α3(H126R) mice
expressing BZ-insensitive α3-subtype GABAARs. The latter approach (iii) was employed
as we were unable to obtain a reliable α2-selective GABAAR PAM. Thus, a combination
of selective drug and point mutant mice was used. The Ki value of L-838417 to α5subtype GABAARs was ~3 times as high as that of α2- and α3-subtypes in a radioligand
binding assay, although the efficacy of L-838417 at α5-subtype GABAARs was
comparable to that of α2- and α3-subtypes (McKernan et al., 2000). Since the α5-subtype
GABAARs have a much lower expression profile in the whole brain when compared to
α1-, α2, and α3-subtypes (Whiting, 2003), and are considered non-essential in mediating
BZ-induced anxiolysis (Collinson et al., 2002), we argue that the anxiolytic-like effect
seen in this experiment should be predominantly due to the selective positive modulation
of α2-subtype GABAARs.
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Systemic Injection of Non-selective BZ
We examined the presence (or absence) of anxiolytic-like effects elicited by
systemic administration of non-selective BZ to animals where a specific α-subtype was
rendered BZ-insensitive. We tested whether the anxiolytic-like effect of systemic BZ
treatment was blunted in α1(H101R), α2(H101R) or α3(H126R) mice as measured by the
EPM. A similar line of study was previously conducted (K. S. Smith et al., 2012). We
extended that study by including female subjects in our experiment and examining
whether the anxiolytic-like effects of systemic BZ treatment are sex-dependent.
Intra-BLA Microinjection of Selective GABAAR PAMs
Since the BLA is known to be a crucial brain region in mediating anxiety-like
behaviors and anxiolytic-like effects of BZs (M. Davis, 2000; Green & Vale, 1992; Heldt
& Ressler, 2006; Pesold & Treit, 1995; Sanders & Shekhar, 1995), we examined the
presence (or absence) of anxiolytic-like effects elicited by administration of selective
positive modulators of α1-, α2- and/or α3-subtype GABAARs within the BLA. To
achieve this, we assessed the anxiety-like behaviors using the EPM after administration
of subtype selective pharmacological agents via intra-BLA microinjection. Mice were
tested for anxiety-like behaviors after intra-BLA administration of one of the following
drug treatments: (i) Zolpidem, a α1-selective GABAAR PAM; (ii) TP003, a α3-selective
GABAAR PAM; (iii) a combination of selective drug, L-838417, and point mutant mice,
α3(H126R), was used to achieve selective positive modulation of the α2- and α5subtypes, as described in an earlier section. Since the expression of α5-subtype is low in
the amygdala compared to α1-, α2- and α3-subtypes (Fritschy & Mohler, 1995;
Mathiasen, Rodgers, & Mirza, 2007; Pirker et al., 2000), the effects seen should be
predominantly due to the positive modulation of α2-subtypes.
Intra-BLA Microinjection of Non-selective BZ
We also examined the presence (or absence) of anxiolytic-like effects elicited by
intra-BLA administration of non-selective BZ in animals where a specific α-subtype was
rendered BZ-insensitive. To achieve this, we investigated whether the anxiolytic-like
effects of intra-BLA microinjection of BZ were blunted in α1(H101R), α2(H101R) or
α3(H126R) mice as measured by the EPM.
The current view that α2-subtype GABAARs are necessary for mediating BZinduced anxiolysis comes from studies showing that the anxiolytic-like effects of BZ
were ablated in point mutant mice with BZ-insensitive α2-subtype GABAARs, as
assessed by the EPM (Low et al., 2000; K. S. Smith et al., 2012). In our experiments, we
used the combination of subtype selective drugs and point mutant mice to gain further
insights into the differential roles α1-, α2-, and α3-subtype GABAARs play in anxiety and
BZ-induced anxiolysis.
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CHAPTER 2.

LITERATURE REVIEW

Clinical Aspects of Anxiety Disorders
Anxiety disorders are common psychiatric conditions with a 28.8% lifetime
prevalence among U.S. adults and cause significant economic burden to both patients and
society (Kessler et al., 2005; Kessler & Greenberg, 2002). They are an umbrella of
several specific disorders, including, but not limited to, generalized anxiety disorder,
phobias, and panic attacks (American Psychiatric Association, 2000). Normal levels of
anxiety and fear are essential for vigilance and adaptation towards a threat uncertainty,
and dissipate quickly when signals that indicate safety arise. However, pathological
anxiety and fear during the interpretation and response towards threat uncertainty are
maladaptive and can cause suffering of the subject (Grupe & Nitschke, 2013).
Anxiety disorders can be managed by both psychotherapy and pharmacotherapy
in the clinic. Various modalities of psychotherapy were developed or adapted to treat
anxiety disorders with promising effectiveness, such as cognitive behavioral therapy and
interpersonal psychotherapy (Graham & Milad, 2011; Markowitz, Lipsitz, & Milrod,
2014). Several lines of pharmacotherapy options are also available, such as
antidepressant (SSRIs and SNRIs), azapirones, and benzodiazepines (Chessick et al.,
2006; Farach et al., 2012; Katzman et al., 2014; Reinhold & Rickels, 2015). However,
these traditional treatment options have several limitations, such as significant side
effects, or prolonged delay before the onset of efficacy, see the "Clinical Significance"
section in Chapter 1.
Animal Models for Assessing Fear and Anxiety-like Behaviors
The terms “fear” and “anxiety” co-occur very often in the literature and are
indeed deeply intertwined with each other (Suinn, 1969). In recent years, the distinctive
differences between anxiety and fear have become increasingly recognized from both
behavioral and neural circuitry points of view, and the different but overlapping
underlying neural circuitries are being elucidated (M. Davis, Walker, Miles, & Grillon,
2010; Perusini & Fanselow, 2015; Tovote, Fadok, & Lüthi, 2015). In animals, the
predatory imminence theory provides an accepted distinction between fear, and anxiety
(Perusini & Fanselow, 2015).
To study the neurological basis of anxiety and fear, researchers have long used the
behaviors of animals as models of these complex human emotions. To validate an animal
behavioral paradigm as a tool to study the emotion of fear and anxiety, face validity
(whether the test appears to measure the emotion), construct validity (whether the
parameter collected reflects the underlying emotion), as well as predictive validity
(whether the test can predict other measures of the emotion) must be met, although these
standards are evolving (Belzung & Lemoine, 2011; Walf & Frye, 2007; Willner, 1984).
In animals, the anxiety-like and fear-like behaviors are usually measured by their

5

responses to either (i) a potential, non-specific threat, such as exposure to an open space;
(ii) a specific, but unconditioned threat, such as exposure to a predator odor; or (iii) a
specific, conditioned, but non-imminent cue, such as an environmental context which is
experimentally associated with a distinctive aversive stimulus, or (iv) a specific,
conditioned, and imminent cue which is experimentally associated with a distinctive
aversive stimulus, e.g. (Goosens & Maren, 2001; Wilson & Junor, 2008). Further, stressinduced behavioral alterations and social interaction tests are also commonly used (File &
Hyde, 1979; Fuchs & Fliugge, 2006; Zethof, Van der Heyden, Tolboom, & Olivier,
1995).
In rodents, anxiety-like behaviors are assessed by behavioral paradigms such as
open field, EPM, light dark box, defensive burying test, social interaction test, and stressinduced hyperthermia test. Conversely, fear-like behaviors are typically assessed
following a training session where punishing stimuli are delivered, such as Pavlovian
conditioning paradigms (Adriaan Bouwknecht, Olivier, & Paylor, 2007; Bailey &
Crawley, 2009; Blanchard, Griebel, & Blanchard, 2003; Curzon, Rustay, & Browman,
2009; M. Davis, 1993; File, 1980; Njung'e & Handley, 1991; Pellow & File, 1986).
In animals, experimental exposures to stressful or aversive stimuli, brain lesions,
and genetic / pharmacological manipulations can produce excessive fear and anxiety-like
behaviors which serve as models of pathological conditions in humans. It is reported that
stressful events, such as immobilization, maternal separation, and social defeat might lead
to heightened state of anxiety in rodents (Huang et al., 2015; Kedia & Chattarji, 2014;
Romeo et al., 2003). Recent study also reveals that mice display an elevated state of fear
and anxiety following exposure to closed-head mild traumatic brain injury (Heldt et al.,
2014). These models are particularly useful in mimicking various clinical conditions
where pathological anxiety is induced by a known stressor.
In this study, we used the EPM test, a validated behavioral paradigm to measure
anxiety in rodents (Pellow & File, 1986; Walf & Frye, 2007), to study the differential
anxiolytic-like effects of various GABAAR PAMs and the differential contributions of
α1-, α2-, and α3-subtype GABAARs to anxiety-like behaviors.
Brain Areas and Neurotransmitters Involved in Fear and Anxiety
Brain areas and their associated neurocircuitries that mediate fear and anxiety are
highly conserved across a wide range of species (Adolphs, Tranel, Damasio, & Damasio,
1995; Davies, Martinez-Garcia, Lanuza, & Novejarque, 2002; Janak & Tye, 2015). This
is not surprising when considering the evolutionary importance of adaptive fear and
anxiety in the survival of most species (Marks & Nesse, 1994; Ohman & Mineka, 2001;
Price, 2003). While many brain regions participate in the generation and modulation of
fear and anxiety behaviors, the amygdala, bed nucleus of the stria terminalis (BNST),
hippocampus, hypothalamus, periaqueductal grey (PAG), and prefrontal cortex are well
recognized as playing important roles in these processes (Avery, Clauss, & Blackford,
2015; Bishop, Duncan, Brett, & Lawrence, 2004; Graeff, 2007; Graeff, Silveira,
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Nogueira, Audi, & Oliveira, 1993; Tovote et al., 2015). These regions are admittedly not
exclusively involved in fear and anxiety processes and both past and continued research
recognizes that other brain areas, such as the lateral septum, also participate in these
processes (Anthony et al., 2014).
The precise balance of neurotransmitter release in these brain areas is critical for
their normal functions, e.g. (Gao et al., 2014; Prager, Bergstrom, Wynn, & Braga, 2015).
Over the past few decades, a number of neurotransmitters have been identified to be
involved in mediating fear and anxiety, including but not limited to, GABA, serotonin,
norepinephrine, neurosteroids, and acetylcholine (Charney, Heninger, & Breier, 1984;
Feighner & Boyer, 1989; File, Gonzalez, & Andrews, 1998; Hoehn-Saric, 1982;
Kavaliers, Wiebe, & Galea, 1994). The roles these neurotransmitters and their receptors
play in mediating anxiety and fear within the amygdala, BNST, and hippocampus are of
great interest and are reviewed in the following sections.
Amygdala
The amygdala complex is often divided into three major subdivisions: the
basolateral amygdala (BLA), the central nucleus (CeA), and the medial nucleus (MeA)
(Butler et al., 2012). Sensory input from cortical and thalamic regions converge to the
BLA. In turn, the BLA sends efferent projections to separate subdivisions of the CeA and
further project to various brain regions including the hypothalamus and the PAG (Janak
& Tye, 2015).
Amygdalar structure and fear / anxiety
In humans, damage to the BLA results in impairments in conditioned fear
acquisition and fear recognition, as well as decreases in levels of anxiety (Adolphs et al.,
2005; Dellacherie, Hasboun, Baulac, Belin, & Samson, 2011; Klumpers, Morgan,
Terburg, Stein, & van Honk, 2015). Currently, there is limited evidence available
regarding the impact of specific focal lesions of the CeA in human; although, it is
reported that the impairments in fear recognition are comparable between humans with
complete unilateral amygdala damage and unilateral BLA damage that spares the CeA
(Dellacherie et al., 2011).
Most evidence revealing the role the amygdala plays in fear and anxiety comes
from animal studies. Lesions of the CeA in adolescent rhesus monkeys resulted in the
suppression of fear expressions when they were confronted with potentially threatening
stimuli (Kalin, Shelton, & Davidson, 2004), although neonatal amygdalar lesions resulted
in an impaired but not abolished fear response in macaques, suggesting that although
amygdala is an important structure for mediating fear response, other parallel pathways
also exist during development (Kazama, Heuer, Davis, & Bachevalier, 2012). Lesions of
the BLA in rats lead to impaired conditioned avoidance, but left intact behavioral
suppression response to the conditioned aversive stimulus, while CeA lesions resulted in
reduced conditioned behavioral suppression, but left intact conditioned avoidance,
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suggesting a marked distinction between the contribution of BLA and CeA to fear
response (Killcross, Robbins, & Everitt, 1997). More recent studies showed that both
lateral amygdala and CeA lesions, as well as disconnection between the two regions,
resulted in deficits in fear processing and conditioned suppression (Campese, Gonzaga,
Moscarello, & LeDoux, 2015). Lesions of the CeA in rats resulted in reduction of stressinduced anxiety as measured by the EPM, as well as both contextual and cued-fear in a
fear conditioning paradigm (Möller, Wiklund, Sommer, Thorsell, & Heilig, 1997;
Sullivan et al., 2004; Ventura-Silva et al., 2013). Lesion of the MeA or BLA in mice also
lead to reduction of anxiety (Wang, Zhao, Liu, & Fu, 2014). These studies suggested an
indispensable and complex role of amygdala in mediating fear and anxiety-like
behaviors.
In addition to classic lesion studies, the use of advanced circuitry mapping
approaches, such as optogenetics (Boyden, 2011; Boyden, Zhang, Bamberg, Nagel, &
Deisseroth, 2005), has added to the growing evidence supporting the key role the
amygdala plays in mediating fear and anxiety. Overall, non-selective activation of BLA
somata resulted in an anxiogenic outcome (Tye et al., 2011). On a projection-specific
level, it is reported that optogenetic activation of the BLA to medial prefrontal cortex
(mPFC) projection resulted in elevated anxiety-like behaviors while optogenetic
inhibition of the pathway resulted in anxiolytic-like outcomes (Felix-Ortiz, BurgosRobles, Bhagat, Leppla, & Tye, 2015). Similar behavioral effects of optogenetic
manipulation on social interaction were also found upon stimulating or inhibiting the
BLA to ventral hippocampus projection (Felix-Ortiz & Tye, 2014). However, it is
reported that optogenetic activation of the BLA to anterodorsal BNST projection, as well
as the BLA to CeA projection, elicited anxiolytic-like effects (Kim et al., 2013; Tye et al.,
2011). These studies suggested that although the net output of BLA projection likely
produces an anxiogenic profile, the projections from BLA to different brain areas have
distinct and, in some cases, opposite effects.
Amygdalar GABAergic signaling and fear / anxiety
The pivotal role amygdala plays in anxiety and fear is also supported by
numerous pharmacological studies that employed local manipulation of various
neurotransmitters and receptors. For example, intra-BLA microinjection of BZs elicited
anxiolytic-like effects, whereas intra-BLA microinjection of GABAAR antagonists
produced an anxiogenic-like outcome (M. Davis, 2000; Green & Vale, 1992; Heldt &
Ressler, 2006; Pesold & Treit, 1995; Sanders & Shekhar, 1995). Intra-CeA
microinjection of midazolam elicited anxiolytic-like effects as measured by the shockprobe burying paradigm but not the EPM. Thus, the anxiolytic-like effects of BZ
manipulation in the CeA appeared to be task-dependent (Pesold & Treit, 1995). Other
studies reported that microinjections of the GABAAR agonist muscimol into the CeA,
rather than the BLA, produced anxiolytic-like effects as measured by the EPM (Moreira,
Masson, Carvalho, & Brandão, 2007). The results from these two studies suggested
differential effects of benzodiazepines (GABAAR positive allosteric modulators) versus
muscimol (GABAAR agonist) when microinjected to the BLA. Taken together, these
studies suggested that GABAergic neurotransmission in the amygdala mainly inhibits
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fear and anxiety. However, at present, the effects of microinjection of GABAAR subtype
selective compounds in the amygdala remains largely unclear due to limited supporting
evidence.
A number of subpopulations of GABAergic interneurons reside in the amygdala
complex. They can be divided roughly into the following three groups: a parvalbuminpositive population, a cholecystokinin-positive population, and a somatostatin-positive
population (Spampanato, Polepalli, & Sah, 2011 ; Wolff et al., 2014). It is reported that
both parvalbumin and somatostatin interneurons in the BLA are implicated in fear
learning via an indirect parvalbumin-somatostatin-pyramidal neuron dis-inhibitory
microcircuit (Wolff et al., 2014). Increased number of parvalbumin neurons was
correlated with reduced anxiety-like behaviors in a study that investigated the effects of
exposure to enriched environment (Urakawa et al., 2013). Another study showed that the
paraventricular nucleus of the thalamus innervated the somatostatin interneurons in the
lateral CeA and this pathway is implicated in the control of fear processing (Penzo et al.,
2015).
Other amygdalar neurotransmitters and fear / anxiety
Besides GABAergic signaling, many other neurotransmitters, such as dopamine
and serotonin, are also implicated in anxiety and fear-like behaviors in the amygdala. A
number of studies, reviewed by de la Mora: (de la Mora, Gallegos-Cari, ArizmendiGarcia, Marcellino, & Fuxe, 2010), showed that microinjection of a dopamine D1
receptor agonist to the amygdala (both the BLA and the CeA) elicited anxiogenic-like
effects while microinjection of a D1 receptor antagonist resulted in anxiolytic-like
effects; further, microinjection of a D2-like receptor antagonist in the BLA resulted in
anxiolytic-like effects while microinjection of a D2-like receptor antagonist in the CeA
produced paradoxical, task-dependent anxiogenic / anxiolytic-like effects (Greba,
Gifkins, & Kokkinidis, 2001; F.A. Guarraci, Frohardt, Falls, & Kapp, 2000; F. A.
Guarraci, Frohardt, & Kapp, 1999; Lamont & Kokkinidis, 1998; Perez de la Mora et al.,
2012). A study found that dopamine interacted with GABAergic signaling by inhibiting
GABA release from parvalbumin-positive interneurons in the BLA (Chu, Ito, Li, &
Morozov, 2012; Pape, 2005). This finding offered a possible explanation for dopaminedriven disinhibition of the amygdala and subsequent behavioral outcomes. Another
important neurotransmitter, serotonin, also plays a role in regulating the function of the
amygdala. A study employing a microdialysis approach suggested that serotonin
concentration in the BLA complex was elevated during a conditioned fear test (Zanoveli,
Carvalho, Cunha, & Brandao, 2009). In another study, administration of serotonin to the
amygdala resulted in anxiogenic-like effects as measured by conflict test, whereas
depletion of serotonin in the BLA resulted in anxiolytic-like effects as measured by a
social interaction paradigm and reduced fear response in a conditioned fear test (Hodges,
Green, & Glenn, 1987; Johnson et al., 2015). Thus, both dopaminergic and serotonergic
neurotransmission in the amygdala mainly promote fear and anxiety. This is in contrast
with studies showing anxiolytic-like effects after chronic, systemic SSRI treatment that
augmented extracellular serotonin level over a prolonged period of time (Abuhamdah,
Hussain, Chazot, & Ennaceur, 2015; Dulawa, Holick, Gundersen, & Hen, 2004).
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However, considering the studies that showed acute systemic SSRI treatment indeed
promotes fear and anxiety-like behaviors both in rodents as well as in humans (Burghardt
et al., 2004; Grillon et al., 2007), it is plausible that chronic enhancement of serotonergic
transmission in the amygdala might allow anxiolytic-like effects to develop.
Other neurotransmitters, such as neuropeptides and neurosteroids, are also
involved in the physiological function of the amygdala that controls fear and anxiety. It is
reported that microinjection of neuropeptide Y into the BLA, but not CeA, elicited
anxiolytic-like effects as measured by a social interaction paradigm (Sajdyk, Vandergriff,
& Gehlert, 1999). Knockdown of cholecystokinin peptide by shRNA in the BLA elicited
anxiolytic-like effects as measured by the EPM (Del Boca, Lutz, Le Merrer, Koebel, &
Kieffer, 2012). Microinjection of a neurosteroid, allopregnanolone, into the amygdala
resulted in anxiolytic-like effects as measured by both EPM and a defensive burying task
(Engin & Treit, 2007a). These findings indicated that there is complexity due to the
multitude of neurotransmitters in the amygdala and prompted further investigation of
neurochemical dysregulation in the amygdala in the context of fear and anxiety.
All of the abovementioned studies, ranging from lesion studies, optogenetic
studies, pharmacological studies and behavioral studies, support the major role the
amygdala plays in mediating fear and anxiety. It is also worth pointing out that due to
multiple effects of various projections, microcircuitries, and neurotransmitters in the
amygdala, it is particularly interesting to dissect out the molecular and cellular causes of
these phenomena.
Bed Nucleus of the Stria Terminalis
The bed nucleus of the stria terminalis (BNST) belongs to the extended amygdalar
structure (Swanson & Petrovich, 1998) and receives prominent inputs from the amygdala.
Similar to the CeA, which also receives direct projection from the BLA, the BNST gives
rise to projections that target common downstream brain areas such as the hypothalamus,
and has been implicated in behaviors such as stress responses and anxiety. However,
unlike the CeA, which mediates fast expression of fear and anxiety, the BNST is thought
to be an important player in the orchestration of slow onset, prolonged fear and anxiety
responses (Dong, Petrovich, & Swanson, 2001; Haufler, Nagy, & Pare, 2013; Sakanaka,
Shibasaki, & Lederis, 1986; Spencer, Buller, & Day, 2005; Walker, Toufexis, & Davis,
2003) .
Lesions of the BNST resulted in selective impairment of contextual fear but not
cued-fear, which was in contrast to CeA lesions that impaired both functions (Sullivan et
al., 2004). Inactivation of BNST blocked defensive responses towards fox odor as well as
alarm pheromones in rodents (Breitfeld et al., 2015; Fendt, Endres, & Apfelbach, 2003).
These findings suggested that BNST is largely responsible for behavior responses to the
environmental context.
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The role that the BNST plays in fear and anxiety is further elucidated by several
optogenetics studies. Importantly, a study revealed that the two subdivisions of BNST
showed opposite functions, in which activities in the oval BNST sub-nucleus increased
anxiety and activities in the anterodorsal BNST sub-nucleus inhibited anxiety. Also,
photostimulation of the BLA to anterodorsal BNST projection elicited anxiolytic-like
effects as measured by the EPM test (Kim et al., 2013). It was reported that
photostimulation of the glutamatergic BNST to ventral tegmental area (VTA) projections
resulted in an anxiogenic-like outcome whereas photostimulation of the GABAergic
BNST to VTA projections lead to anxiolytic-like outcome (Jennings et al., 2013). These
results demonstrated how BNST is intertwined with other brain regions, such as the BLA
and the VTA, to orchestrate the fine tuning of fear and anxiety-like behaviors.
GABAergic transmission is shown to be involved in mediating a number of
physiological functions and behavioral outcomes in the BNST. A study reported that
deletion of the α1-subunit of GABAARs in the corticotropin-releasing factor-positive
(CRF+) neurons (CRF-α1 KO) resulted in an anxiogenic outcome, which could be
rescued by intra-BNST microinjection of a CRF antagonist. Same study also showed that
microinjection of the α1-subtype selective PAM zolpidem in the BNST elicited
anxiolytic-like effects in WT but not CRF-α1 KO mice (Gafford et al., 2012). Further,
norepinephrine signaling in the ventral BNST was shown to be crucial for fear responses
towards fox odor in rodents. A study reported that the noradrenaline level in the ventral
BNST was significantly increased in response to trimethylthiazoline exposure, and
microinjection of clonidine, a α2-adrenergic agonist that lowers noradrenaline level, in
the ventral BNST abolished fox odor induced fear potentiation (Fendt, Siegl, & SteinigerBrach, 2005). Further, sex hormones and neurosteroids are both implicated in modulating
fear and anxiety-like behaviors in the BNST (Nagaya, Acca, & Maren, 2015; Toufexis,
2007).
To sum up, the BNST constitutes an integral part of the extended amygdalar
structure, and together with the BLA and CeA, they control a large range of emotional
responses and exert interconnected and inter-balanced effects via multiple projections.
Hippocampus
Hippocampal formation (short-hand as “hippocampus” in the following text) can
be roughly divided into dorsal and ventral portions, and further subdivided into several
fields, including cornus ammoni (CA)1, CA2/CA3, and dentate gyrus (DG) (Amaral &
Lavenex, 2007). Studies have shown that lesions of the ventral hippocampus lead to
impairment of normal expression of anxiety, and it is believed that while the dorsal
hippocampus is mostly involved in memory processing, the ventral hippocampus is
mostly involved in anxiety (Bannerman et al., 2003; Bannerman et al., 2004).
A recent optogenetic study revealed that the DG was differentially involved in
anxiety versus fear. It was reported that the dorsal division was more involved in
contextual fear encoding, whereas the ventral division was more involved in innate
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anxiety, signifying the dissociation of the differential functional roles played by the intrahippocampal subdivisions (Fournier & Duman, 2013; Kheirbek et al., 2013). The
connection from BLA to ventral hippocampus is also implicated in social anxiety (FelixOrtiz & Tye, 2014).
Intra-hippocampal microinjection of BZ, among many other compounds, such as
certain serotoninergic agonists and neurosteroids, results in anxiolytic-like effects (Engin
& Treit, 2007b). A recent study utilizing intra-BLA microinjection of subtype selective
GABAAR ligands revealed that the anxiety-like behaviors were mediated by the α2subtype GABAARs in the ventral hippocampus, whereas fear memory processing was
mediated by the α5-subtype GABAARs in the dorsal hippocampus (McEown & Treit,
2013).
To sum up, the hippocampus is a complex structure with multiple functions. The
ventral hippocampus is an important brain structure that receives input from the BLA and
is implicated in anxiety-like behaviors, whereas the dorsal hippocampus is more involved
in learning, memory and fear-related behaviors.
The Differential Functional Roles of GABAAR Subtypes
Most attempts to determine the contribution of the α1-, α2-, α3-, and α5-subtypes
GABAARs in mediating behaviors have come from studies examining the effects of
classic BZs (such as diazepam, chlordiazepoxide, midazolam, etc.) and other BZ-like
ligands (such as zolpidem, L-838417, and TP003). These compounds often differ in their
affinity and efficacy for different α-subtypes, and those that display preferential affinity
and/or efficacy towards particular α-subtypes are referred to as subtype selective drugs.
In combination with the use of these GABAAR ligands and genetically modified mice
(KO, point-mutants), past studies have elucidated various functional differences among
different α-subtype GABAARs.
The α1-subtype GABAARs
Currently, the role that α1-subtype GABAARs play in fear and anxiety is unclear.
In mice, systemic injection of α1-subtype selective antagonists blocked BZ-induced
anxiolysis as measured by the EPM, suggesting an important role of α1-subtype in
mediating BZ-induced anxiolysis (Belzung et al., 2000). Likewise, in mice that express
BZ-insensitive α1-subtype GABAARs, i.e. the α1(H101R) mice, BZ-induced inhibition of
a conditioned fear response was abolished, suggesting that α1-subtype GABAARs are
necessary for the effects of BZ on fear-like behaviors (K. S. Smith et al., 2012). In
contrast, the study showed that BZs retained their anxiolytic-like effects in α1(H101R)
mice as measured by the EPM test, suggesting that the α1-subtype is not essential for BZinduced anxiolysis (K. S. Smith et al., 2012). The fact that systemic injection of zolpidem
produced debatable anxiolytic-like effects that were sensitive to experimental conditions
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such as illumination of the maze (Savic et al., 2004) suggested that the role α1-subtype
GABAARs play in mediating anxiolysis was influenced by complex variables.
In contrast to its role in fear and anxiety-like behaviors, the role the α1-subtype
plays in sedation, aggression, amnesia and in addiction to BZs is better understood. The
sedative effects of diazepam were abolished in the α1(H101R) mice, suggesting the
involvement of α1-subtype GABAARs in sedation (McKernan et al., 2000). Similarly, the
aggression-promoting effects of midazolam were abolished in α1(H101R) mice in a
social interaction paradigm, suggesting the involvement of α1-subtype GABAARs in BZinduced escalation of aggression (Newman et al., 2015). Further, it is reported that
systemic administration of β-CCT, a α1-subtype selective antagonist, reduced alcoholinduced aggressive behaviors. However, interestingly, systemic administration of
zolpidem did not increase ethanol-induced aggression, which could be attributed to the
sedative effects of zolpidem (de Almeida, Rowlett, Cook, Yin, & Miczek, 2004). The
amnesic effects of diazepam, as assessed by a passive-avoidance paradigm, was also
abolished in α1(H101R) mice, suggesting the involvement of α1-subytpe GABAARs in
memory processing (Rudolph et al., 1999). Similarly, amnesic / motor-impairing effects
were also observed following systemic administration of zolpidem (Cope et al., 2004;
Zanin et al., 2013), further reviewed in (Fitzgerald et al., 2014). Other studies have
implicated α1-subtype GABAARs in drug abuse and addiction (Rowlett & Lelas, 2007;
Tan, Rudolph, & Luscher, 2011), as well as in anxiety induced by acute BZ-withdraw
(Divljakovic et al., 2013).
Several studies have begun to elucidate the specific roles played by α1-subtype
GABAARs in different brain areas. Deletion of α1-subtype GABAARs within the
amygdala reportedly disrupted the anticonvulsant and sedative effects of BZ. However,
the anxiolytic-like effects of BZ, as measured by the EPM, were unaffected, suggesting
that the α1-subtype is not essential for amygdala-mediated anxiety-like behaviors (Heldt
& Ressler, 2010). Conversely, microinjection of zolpidem to the BNST resulted in
anxiolytic-like effects, as measured by the open field test (Gafford et al., 2012). These
results suggest that the role played by α1-subtype GABAARs in fear and anxiety-like
behaviors is brain region specific.
Together, current evidence suggests that the α1-subtype GABAARs are involved
in sedative, amnesic, and addictive effects of BZs (Rudolph & Knoflach, 2011). On the
basis of currently published studies, the relative importance of the α1-subtype GABAARs
in mediating BZ-induced anxiolytic-like behaviors is ambiguous, however its role may
depend upon the specific brain regions, the behavioral test conditions, and the particular
responses used to assess anxiety-like behaviors.
The α2-subtype GABAARs
The role that α2-subtype GABAARs play in BZ-induced reductions of fear and
anxiety-like behaviors is well documented. The inhibitory effects of diazepam and CDP
on anxiety-like behavior, as measured by the EPM, and fear-like behavior, as measured
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by fear potentiated startle test, were reduced in α2(H101R) mice (Low et al., 2000; K. S.
Smith et al., 2012). Genomic deletion of the α2-subunit also abolished the anxiolytic-like
effects of diazepam (Dixon, Rosahl, & Stephens, 2008). In contrast, a study showed that
the sedative effects of diazepam were weakened in α1(H101R) mice that possess BZsensitive α2-subtype GABAARs when compared to induced sedation in WT mice
(McKernan et al., 2000). This evidence suggests that α2-subtypes are not overtly
involved in BZ-induced sedation.
The above findings showing that lack of involvement of α2-subtype in sedation
support the theory that α2-subtype selective PAMs might be good candidates for use as
day-time anxiolytic drugs, as the sedative effects of classic BZs are problematic for their
day-time use (Rudolph & Knoflach, 2011). In recent years, two compounds that have
preferential efficacy at both α2- and α3-subtype GABAARs, TPA023 and TPA023B, have
been developed and tested in animal experiments as well as clinical trials. In both animals
and humans, these compounds reduce anxiety without major sedative effects even at high
dose, however, issues with toxicity complicated the continuation of a clinical trial (Atack,
2010b; Atack, Wafford, et al., 2006).
The putative α2-subtype selective agonist TCS-1105 (also known as “compound
1c”) reportedly exerted anxiolytic-like effects as measured by the light-dark box test
(Taliani et al., 2009). However, since the selectivity of this compound was tested in
α1β2γ2, α2β2γ2, and α5β3γ2 recombinant GABAARs, but not α3-containing GABAARs,
the selectivity of this compound in α2-subtype versus α3-subtype is unclear at present.
Currently, a reliable α2-subtype selective compound is sought-after by the field.
The α2-subtype GABAARs are also implicated in regulating depression-like
behaviors (Engin, Liu, & Rudolph, 2012; Vollenweider, Smith, Keist, & Rudolph, 2011)
and the myorelaxation effects of BZs in mice (Crestani et al., 2001). Further, recent
pharmacological studies as well as human genetics revealed that α2-subtype GABAARs
are also involved in reward-related behaviors and addiction (Dixon et al., 2010; Engin et
al., 2014). This evidence might argue against the use of α2-selective PAM for anxiety
management as habit-forming might be a possible side-effect.
To sum up, current evidence suggests that α2-subtype GABAARs are implicated
in anxiety-like, depression-like and schizophrenia-like behaviors and are a promising
target for the development of novel therapeutics (Engin et al., 2012).
The α3-subtype GABAARs
Currently, the role that α3-subtype GABAARs play in fear and anxiety is still
debatable. On one hand, in an experiment using point mutant mice, it is reported that
systemic injection of diazepam retained its effects in inducing anxiolysis as well as fear
reduction in α3(H126R) mice carrying BZ-insensitive α3-subtype GABAARs (K. S.
Smith et al., 2012). Genomic knockout of the α3-subunit did not affect baseline anxiety
behavior or diazepam-induced anxiolysis (Yee et al., 2005). These findings suggest that
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the α3-subtype GABAARs are not essential for mediating anxiety and BZ-induced
anxiolysis. On the other hand, studies using the α3-subtype selective PAM TP003
showed that systemic injections produced anxiolytic-like effects, as measured by the
EPM and stress-induced hyperthermia in rodents as well as by a conflict test paradigm in
primates (Dias et al., 2005; Fischer et al., 2011). In a conditioned emotional response
paradigm, the α2-, α3- and α5-subtype selective compound, L-838417 retained its
anxiolytic-like effects in α2(H101R) mice, suggesting that α3- and/or α5-subtype
GABAARs mediate L-838417-induced anxiolysis independent of α2-subtype GABAARs
(Morris, Dawson, Reynolds, Atack, & Stephens, 2006). In another study, the systemic
injections of the α3-subtype selective BZ-site inverse agonist named Alpha3IA produced
an anxiogenic-like profile as measured by the EPM in rodents (Atack et al., 2005).
Together, these studies suggest that selective modulation of α3-subtype GABAARs by
BZ-site ligands is sufficient to alter anxiety-like behaviors. Further, it is reported that
blockade of 5-HT1A receptors reversed the anxiolytic-like effects elicited by TP003 in a
stress-induced hyperthermia paradigm. This finding suggests that α3-subtype GABAARs
are involved in the interaction between GABAergic and serotonergic transmission
(Vinkers, van Oorschot, Korte, Olivier, & Groenink, 2010). Together, current findings
suggest that α3-subtype GABAARs play a sufficient, but not necessary role in mediating
anxiety-like behaviors and BZ-induced anxiolysis.
Similar to α2-subtypes, it is generally accepted that α3-subtype GABAARs are not
overtly involved in BZ-induced sedation as diazepam failed to elicit sedative effects in
α1(H101R) mice with intact α3-subtype GABAARs at doses that would induce sedation
in WT mice (McKernan et al., 2000). It is also reported that α3-subtype GABAARs
appeared to be non-essential for mediating the effects of BZ on sleep EEG (Kopp,
Rudolph, Keist, & Tobler, 2003). Lack of α3-subtype GABAARs resulted in
hyperdopaminergic and schizophrenia-like behavioral phenotypes hallmarked by
sensorimotor gating deficits which could be reversed by treatment of antipsychotic drug
haloperidol, suggesting that α3-subtype GABAARs’ involvement in schizophrenia (Yee et
al., 2005). Similar to α2-subtype, the α3-subtype GABAARs are also involved in
myorelaxation effects of BZs in rodents as well as in primates (Crestani et al., 2001;
Fischer et al., 2011). Currently, little is known about whether the α3-subtype GABAARs
are also involved in the addictive property of BZs or not.
To sum up, current evidence suggests that α3-subtype GABAARs play a role in
mediating anxiolytic-like and myorelaxative, but not sedative effects of BZs. The α3subtype GABAARs are also implicated in schizophrenia-like behaviors in rodents.
The α5-subtype GABAARs
The α5-subtype GABAARs differed from α1-, α2-, and α3-subtypes in that their
expression, on the protein level, is enriched the olfactory bulb, hippocampus and spinal
trigeminal nucleus, and their expression elsewhere is comparatively low (Fritschy &
Mohler, 1995; Mathiasen et al., 2007; Pirker et al., 2000). Further, their subcellular
expression patterns are mainly extrasynaptic and, thus they are thought to mediate tonic
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GABAergic inhibition (Crestani et al., 2002; Farrant & Nusser, 2005; Fritschy, Johnson,
Mohler, & Rudolph, 1998; Groen et al., 2014). Due to the recognized involvement of the
hippocampus in learning and memory processes, the prominent enrichment of α5-subtype
GABAARs in the hippocampus was postulated to play specific roles in mediating learning
and memory. The α5-subunit knockout mice performed better in a spatial learning task
(Collinson et al., 2002), and inverse agonism of the α5-subtype by a compound named L655,708 resulted in cognitive improvement both under normal physiological conditions,
and after general isoflurane-induced anesthesia where short-term memory was markedly
impaired (Atack, Bayley, et al., 2006; Zurek, Bridgwater, & Orser, 2012).
Currently, the evidence for the involvement of α5-subtype GABAARs in anxiety
is limited and contradictory. Mice with genetic deletion of the α5-subunit (α5-subunit
KO) performed similarly to WT mice on the EPM test and in response to BZ (Collinson
et al., 2002). Administration of a α5-subtype selective inverse agonist, α5IA, also did not
significantly alter anxiety-like behaviors in rodents (Dawson et al., 2006). However, a
study indicated that administration of another α5-subtype selective inverse agonist, L655,708, resulted in anxiogenic-like effects in the EPM paradigm (Navarro, Burón, &
Martı́n-López, 2002), although questions were raised as to whether these effects were
indeed mediated exclusively by the α5-subtype GABAARs (Atack, Bayley, et al., 2006).
Together, currently the majority evidence suggests that the α5-subtype GABAARs appear
unnecessary for mediating anxiety-like behaviors.
The α4- and α6-subtype GABAARs
The α4- and α6-subtype GABAARs differ from the abovementioned receptor
subtypes, in that they are insensitive to BZs due to the lack of (i) a crucial histidine
residue required for the formation of functional BZ-site, and (ii) their preferential
association with the δ-subunit (Caruncho & Costa, 1994; Sur et al., 1999; Wafford et al.,
1996; Wieland, Lüddens, & Seeburg, 1992). They are known to mediate extrasynaptic
tonic GABAergic inhibition (Belelli et al., 2009; Brickley & Mody, 2012; Farrant &
Nusser, 2005; Hamann, Rossi, & Attwell, 2002).
One feature of α4-subtype GABAARs is their sensitivity towards neurosteroid and
hormonal modulation. This sensitivity was postulated to be involved in mediating many
sex-differences in anxiety states, such as premenstrual, post-partum as well as peripuberty anxiety (Gulinello, Gong, Li, & Smith, 2001; Gulinello, Orman, & Smith, 2003;
Shen et al., 2007; S. S. Smith et al., 1998). The α4-subtype GABAARs are also regulated
by stress hormones and steroids, such as corticotrophin releasing hormone and 3α,5α[β]THP, and are thought to be a key player in mediating stress and anxiety responses in a
sex dependent manner (Mody & Maguire, 2011; Shen, Mohammad, Ramroop, & Smith,
2013; S. S. Smith, 2013; S. S. Smith, Shen, Gong, & Zhou, 2007).
Limited evidence indicates that α6-subtype GABAARs are involved in regulating
fear and anxiety, amongst other behaviors and physiological functions. One report
showed that midazolam-induced anxiolysis is attenuated in human subjects carrying the
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Pro385Ser mutation in the α6-subunit (Hoffman, Balyasnikova, Mahay, Danilov, &
Baughman, 2002). Some evidence also suggested that genetic variation within the α6subunits is associated with epilepsy in human (Hernandez, Gurba, Hu, & Macdonald,
2011; Hirose, 2014). Also, a reduction of α6-subunit protein expression was reported in
the superior frontal cortex of autistic subjects (Fatemi et al., 2014). Further, α6-subtype
GABAARs are also implicated in alcohol dependency (Loh & Ball, 2000).
In summary, the α4- and α6-subtype GABAARs exhibit distinct physiological,
pharmacological, and functional profiles that set them apart from the other BZ-sensitive
GABAAR subtypes. In this study, we will mostly focus on the GABAAR subtypes that are
both BZ-sensitive and abundantly expressed in the amygdala, i.e., the α1-, α2-, α3subtypes.
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CHAPTER 3.

METHODOLOGY

Mouse Strains
C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine) were used in this study
as WT controls to test the anxiolytic profile of various selective and non-selective
GABAAR PAMs in both systemic and intra-BLA microinjection experiments. This strain
of mice are widely used in behavioral studies and their characteristic patterns of anxiety
and fear-like behaviors are well understood. For example, C57BL/6J showed lower
baseline anxiety level and higher sensitivity to BZ when compared to BALB/c mice
(Lepicard, Joubert, Hagneau, Perez-Diaz, & Chapouthier, 2000), and they also showed
slower fear extinction when compared to DBA/2J mice (Waddell, Dunnett, & Falls,
2004).
In experiments that examined the functional silencing of selective GABAARsubtypes towards the modulatory effects of BZs, GABAAR point mutant mice,
generously gifted by Dr. Uwe Rudolph from McLean Hospital, were used. These strains
of mice were created in the last decade and have become of great value in the
investigation of the selective function of different subunits (Rudolph & Mohler, 2004).
Three lines of point mutant mice were used in our experiment: α1(H101R), α2(H101R),
and α3(H126R). As previously described (Low et al., 2000; Rudolph et al., 1999; K. S.
Smith et al., 2012), these mice have a mutated residue (histidine to arginine) in the BZ
binding site of a particular α-subunit, rendering the receptor insensitive to the modulatory
effects of BZs. These mutant mice were maintained on C57BL/6J genetic background
and bred as homozygotes.
All animals were housed in micro-isolation cages with ad libitum access to food
and water, 12h light-dark cycle and controlled temperature / humidity. All animals used
in this study were adult mice (between 2-6 months of age). For most experiments, male
subjects were used, except for the systemic CDP injection experiment, where mice of
both sexes were used. All testing procedures were conducted in the light-phase of the day
and were approved by the Animal Care and Use Committee of the University of
Tennessee Health Science Center.
Surgery Procedures
Stereotaxic surgeries were performed using procedures previously described in
detail (Heldt & Ressler, 2006). Adult mice were anesthetized with an intraperitoneal (i.p.)
injection of a cocktail of ketamine (80mg/kg) and xylazine (10mg/kg). Upon
confirmation of anesthesia, their heads were shaved, swabbed with betadine, and
mounted in a stereotaxic surgical frame (David Kopf Instruments, Tujunga, CA) with
metal ear bars inserted and secured. Ophthalmic ointment was applied to prevent the eyes
from drying out. An incision along the midline of the skull was made, and the
surrounding skin was retracted to expose the surgical site. Two anchoring screws were
then implanted. Holes were drilled in the skull over the intended cannula implantation
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sites and bilateral 26 gauge guide cannulae (PlasticOne, Roanoke, VA) were planted
stereotaxically at the following coordinates in reference to Bregma : AP:-1.5, ML: ±3.3
or ±3.4, DV: -5.0 or -5.1 according to a reference stereotaxic atlas (Paxinos & Franklin,
2001). The cannula fixture was secured with dental cement and the surgical incision was
closed with adhesives. After surgery, animals were placed on a heating pad for recovery
and a dose of post-operation analgesics (Buprenorphine 0.1 mg/kg or Carprofen 5.0
mg/kg) was administered. Animals were then allowed to fully recover from surgery for at
least 4 days, during this period they were closely monitored for signs of pain and distress.
They were also handled with gloved hand daily to allow acclimation to the gentle
restraint required for the microinjection procedure, and to minimize the stress induced by
the injection procedure preceding the behavioral test.
Pharmacological Agents
Many BZ-site ligands are known to exert positive allosteric modulatory effects on
GABAARs. Non-selective classic BZs (e.g., CDP) are promiscuous to α1-, α2-, α3-, and
α5-subtype GABAARs, on the other hand, subtype selective BZ-site ligands are defined
as having either preferential affinity (e.g. zolpidem) and/or preferential efficacy (e.g. L838417 and TP003) towards a particular subset of BZ-sensitive α-subtypes (Rudolph &
Knoflach, 2011).
Chlordiazepoxide
Chlordiazepoxide (CDP, Sigma Aldrich, St Louis, MO), a classic BZ and
nonselective GABAARs PAM, was used to augment the α1-, α2-, α3-, and α5-subtype
GABAARs in systemic and intra-BLA microinjection experiments. CDP absorbs well
after i.p. injection and a 5mg/kg i.p. injection in rats results in 25% receptor occupancy in
the brain (Dias et al., 2005). For CDP systemic injection experiments, we used 10mg/kg
as the high dose. The dose was chosen based on a previous systemic injection study that
used the same dose as the high dose for mice (K. S. Smith et al., 2012). For CDP
microinjection experiments, we used 20µg/µL as the high dose working concentration
and 0.3µL injection volume was delivered. This was based on a previous microinjection
study that used the same concentration of CDP (20µg/µL) with 0.5µL injection volume as
the high dose for rats (Stackman & Walsh, 1995).
Zolpidem
Zolpidem (Toronto Research Chemicals, North York, ON, Canada), a selective
BZ-site PAM of α1-subtype GABAARs with ~5-fold selectivity over other subtypes
(Petroski et al., 2006), was used to selectively augment α1-subtype GABAARs in both
systemic injection experiments and intra-BLA microinjection experiments. The binding
affinity of zolpidem is drastically reduced in α1(H101R) mice (McKernan et al., 2000).
Zolpidem absorbs well after i.p. injection. In mice, an i.p. dose of 1.8mg/kg results in
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approximately 50% receptor occupancy in the brain (Hopkins, Brian Nofsinger, Allen,
Koch, & Varney, 2009). Ranges of drug dosages used in this study were carefully chosen
based on previously published studies. For the zolpidem systemic injection experiment,
we used 2mg/kg as the high dose. The dose was chosen based on a previous systemic
injection study that used 3mg/kg as the high dose for mice and reported sedative effects
at this dose (Mathiasen, Mirza, & Rodgers, 2008). We also observed pronounced motor
impairment even at 2mg/kg dose that rendered the mice unable to reliably perform in the
EPM test, thus we used 2mg/kg as the high dose for our experiment. For the zolpidem
microinjection experiment, we used 0.5µg/µL as the high dose working concentration
and 0.3µL injection volume was delivered. This was based on a previous microinjection
study that used 0.25µg/µL concentration and 0.5µL injection volume as the working dose
for mice (Gafford et al., 2012).
L-838417
L-838417 (Tocris, Bristol, UK) is a selective BZ-site PAM that binds to α1-, α2-,
α3-, and α5-subtype GABAARs, but only exerts positive modulatory effects on the α2-,
α3-, and α5-subtypes in recombinant receptors. The binding affinity of L-838417 is lower
in α5-subtype when compared to α1-, α2-, α3-subtypes. Further, although no direct
evidence is available about the binding affinity of L-838417 for α3(H126R) receptors, it
is known that the binding affinity of L-838417 is drastically reduced in α1(H101R)
receptors (McKernan et al., 2000). Since both the α1- and α3-subtypes share similar BZsite structure that requires the histidine residue, we deduce that the binding affinity of L838417 should also be lost in α3(H126R) receptors. L-838417 absorbs well after i.p.
injection. In mice, a dose of 1mg/kg or 3mg/kg i.p. injection results in 30-40% receptor
occupancy in the brain (Scott-Stevens, Atack, Sohal, & Worboys, 2005), although a more
recent study reports that the OC50 is around 1.3mg/kg (Hopkins et al., 2009). For the L838417 systemic injection experiment, we used 2mg/kg as the high dose. This dose was
chosen based on a previous systemic injection study that found anxiolytic-like effects at
3mg/kg dose in a Vogel conflict test for mice and in a conditioned emotional response
test for rat (Mathiasen et al., 2008; Mathiasen et al., 2007). In an initial experiment, we
found robust anxiolytic-like effects at 2mg/kg and even with a 0.5mg/kg dose in WT
mice. Thus, we used 2mg/kg as the high dose in our experiment. For the L-838417
microinjection experiment, we used 0.5µg/µL as the high dose working concentration
and 0.3µL injection volume was delivered. This was based on a previous microinjection
study that used 0.4µg/µL concentration and 1µL injection volume as the working dose for
rats (Mathiasen et al., 2007).
TP003
TP003 (Tocris, Bristol, UK) is a α3-subtyp.e selective BZ-site PAM (Dias et al.,
2005; Marowsky, Rudolph, Fritschy, & Arand, 2012). In vitro, TP003 binds to α1-, α2-,
α3-, and α5-subtype GABAARs with high affinity, but only exerts positive modulatory
effects on the α3-subtype in recombinant GABAARs. The binding affinity of TP003 is
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drastically reduced in α2(H101R) receptors (Dias et al., 2005). TP003 absorbs well after
i.p. injection. In rat, a 0.3 mg/kg i.p. injection resulted in 75% receptor occupancy in the
brain (Dias et al., 2005). For TP003 systemic injection experiment, we used 2mg/kg as
the high dose. This dose was chosen based on a previous systemic injection study that
found anxiolytic-like effects at 3mg/kg dose for mice (Dias et al., 2005). In an initial
experiment, we found robust anxiolytic-like effects at 2mg/kg and even a 0.5mg/kg dose
in WT mice, thus we used 2mg/kg as the high dose in our experiment. Presently, to the
best of our knowledge, no studies have attempted microinjection of TP003 in the brain.
For this reason, we chose to use a range of concentrations, which were comparable to that
of zolpidem and L-838417 microinjections, for TP003 microinjection. This was based on
our initial findings showing that TP003 had comparable dose response relationships to
zolpidem and L-838417 at similar concentrations in systemic injection experiments as
measured by the EPM.
Vehicle
Due to the poor solubility of many drugs used in this study in aqueous solutions,
several vehicles were used to accommodate the doses required for particular experiments.
For systemic injection and intra-BLA microinjection of selective drugs, the compounds
were dissolved in a vehicle consisting of 10% DMSO and 20% cyclodextrin in 0.85%
saline. For systemic injection of CDP, the drug was dissolved in 0.85% saline. For intraBLA microinjection of CDP, most groups received drugs dissolved in a vehicle
consisting of 10% DMSO in 0.85% saline, except for the α2(H101R) mice groups, where
half of the mice (balanced numbers across treatment groups) received drugs dissolved in
a vehicle consisting of 10% DMSO and 20% cyclodextrin in 0.85% saline during a
transition period.
Injection Procedures
For the systemic injection experiments, drug solutions were delivered via i.p.
injection 30 min before the EPM test (described below). For microinjection experiments,
0.3µL of drug solution was delivered gradually over the course of 30 seconds using a
5µL Hamilton syringe connected to a 33 gauge microinjector (PlasticOne, Roanoke, VA)
manually. The injector was left in the cannula for 1 min after each injection to reduce
backflow of injected solution. After completing bilateral microinjection, the animal was
returned to a holding cage for 5-8 min before being tested on the EPM.
Elevated Plus Maze
The EPM is a widely used test apparatus for measuring anxiety-related behaviors
in rodents (Pellow & File, 1986). The apparatus used in this study had transparent
plexiglass for the walls and opaque plexiglass for the floor. The dimensions of the maze
are illustrated in Figure 3-1. The maze was located in a dedicated behavioral testing
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Figure 3-1.

Illustration of the Dimension of EPM Apparatus Used in This Study.

Schematic drawing of the dimensions of the elevated plus maze (EPM) apparatus. The
closed arm walls were constructed using transparent plexiglass, and the floor of the maze
was constructed using opaque material
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room and was illuminated with dim ambient light from the ceiling. The experimenter was
located behind a curtain and was invisible to the mice during the test. Video was recorded
during the test (5 min duration) with an overhead camera and the movement of the
subject was tracked by ANY-Maze software (Stoelting, Wood Dale, IL).
Rodents generally have a native aversion to the open and elevated spaces where
they are exposed to the surrounding open environment, and thigmotaxis (in this case, the
tendency to remain in close proximity to the walls of the closed arm) is typically
observed (Filgueiras, Carvalho-Netto, & Estanislau, 2014). Anxiety-like behavior is
traditionally measured by preference for the closed arm over the open arm. Classic
anxiolytic drugs, such as BZs, reportedly reduce an animal’s aversion to the open arm,
e.g. (K. S. Smith et al., 2012). On the other hand, traumatic events, such as exposure to
immobilization stress, typically enhance the aversion to the open arm (Viswanatha,
Shylaja, Sandeep Rao, Santhosh Kumar, & Jagadeesh, 2012).
We measured the commonly reported EPM parameters including the percentage
of time in the open arm, the percentage of open arm entry, and the distance traveled
during the test. We also recorded several parameters that are not often reported in the
EPM tests. First, we observed a subtle difference in the animal’s behavior in the proximal
open arm (where they could quickly flee and hide in the closed arm) as opposed to the
distal open arm (where they were far away from their “safe zone” and were highly
exposed to the surrounding open environment), we collected the time the animal spent in
and the entry to the distal open arm as more sensitive measurements of anxiety-like
behaviors. Second, as we consistently observed the animals’ risk-assessing behavior
characterized by extending their head outside the edge of the open arm to investigate the
surrounding environment, we counted the number of such investigatory behaviors (head
dips) as an index of risk assessment by the subject. Of note, the parameter “head dips”
was operationally defined here as the incidences where the animal extended its head over
the edge of the open arm, rather than as downward movements of the head. Our pilot data
showed a clear increase of this behavior in BZ-treated mice. Together, the EPM test gave
us both the traditional measurements of anxiety in addition to some potentially more
sensitive measurements of the animal’s subtle behaviors on the maze, and allowed us to
reliably quantify the effects of drug treatment on anxiety-like behaviors.
To score the activities in the open or closed arm, the software tracked the animal’s
entire body area to effectively reducing the spurious counts of entry/exit when the animal
hesitantly moved its body around the boundary of the center zone. To count an entry,
80% of the animals' body must enter an open or closed arm. To count an exit, the animal
must fail to retain 70% of its body in an open or closed arm. For activities in the distal
open arm, the software tracked the center of the animal’s body. For counting head dips,
the software tracked the head of the animal. An example of the animal’s behavior on the
EPM with or without BZ treatment is illustrated in Figure 3-2 as an occupancy plot heatmap.
Based on an initial assessment, we found that many of the parameters collected
during the EPM task were correlated with each other. For the clarity of the data
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Figure 3-2.

Illustration of the Effects of BZ on Animals Behavior on the EPM

Typical occupancy plot heat-maps of animals’ behavior on the elevated plus maze (EPM)
with or without benzodiazepine (BZ) treatment. BZ treatment increased the animals’
activity on the open arm (O.A.).
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presentation we reported the following parameters as the main indicators of the animal’s
behavior on the EPM: percentage of time in the open arm (% O.A. Time), percentage of
open arm entry (% O.A. Entry), number of head dips (Head Dips), and overall distance
travelled on the EPM (Distance). The first three measurements are indicators of the
anxiety level and the investigatory behaviors of the subject. The fourth measurement is an
indicator of the motor activity of the subject. Descriptive statistics of other dependent
measures such as distal open arm (D.O.A) Time and number of D.O.A. Entry were
presented in tables.
Data Evaluation and Reduction
After behavioral testing, animals were euthanized and 1% Evan’s blue dye
solution (0.3µL) was microinjected via the guide cannula. Brains were rapidly collected,
frozen over dry ice, and coronally sectioned on a cryostat to verify cannula placement. A
typical spread of dye is illustrated in Figure 3-3. The whole brain images were taken with
a Olympus BX50 microscope (Olympus, Center Valley, PA), stitched together using the
Stitching plugin, and background subtracted using Fiji (Preibisch, Saalfeld, & Tomancak,
2009; Schindelin et al., 2012; Schneider, Rasband, & Eliceiri, 2012).
Subjects with misplaced cannula, as identified by the spread of the dye and the
imprint left by the cannula, were subsequently excluded prior to data analysis (13 out of
204 mice in the intra-BLA microinjection experiments). In most cases, excluded animals
had off-target injection sites that showed significant dye diffusion or cannula tract imprint
in the CeA, cortex, or ventricle.
The EPM is a locomotion-dependent task (Reynolds, McKernan, & Dawson,
2001), and the accurate measurement of anxiety-like indexes, especially the % O.A.
Entry, depends on adequate locomotion of the animal on the maze for reliable
calculation. The average distance traveled during the 5 minutes test period across all
subjects was 9.4 ± 0.2 meters (mean ± SEM). Subjects who traveled less than 2 meters
during the 5 min test period, which occurred rarely (2%), were excluded from statistical
analysis. In most cases, these animals traveled a short distance after placement in the
EPM, and remained immobile for the remainder of the test session. An exception to this
rule was allowed for the experiments with zolpidem, in which we also planned to
examine the anticipated relationship between anxiety and sedation prior to the
experiment. In addition, animals that fell off the maze during the test were excluded from
the study. Finally, a few animals were excluded from analysis due to malfunction of the
video tracking software. In total, 9 out of 204 mice in intra-BLA microinjection
experiment and 6 out of 345 mice in systemic injection experiment were excluded
because of either immobility, displacement from the maze, or tracking problems.
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Figure 3-3.

Illustration of Bilateral Dye Injection Showing the Injection Sites

A typical dye injection result showing successful bilateral microinjections targeting the
basolateral amygdala (BLA), while sparing the central nucleus (CeA).
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Statistical Analysis
For all experiments, a one-way analysis of variance (one-way ANOVA) with %
O.A. Time, % O.A. Entry, Head Dips, and Distance as dependent variables and dose of
the drug as the independent variable were performed to assess the overall differences
among groups. Dunnett's post hoc multiple comparison test (Dunnett, 1955, 1964) was
used to compare drug injected groups against the vehicle injected group to assess the
effects of drug treatment at a particular dose. For the systemic injection of CDP
experiment, because both males and females were used, two-way analysis of variance
(two-way ANOVA) with % O.A. Time, % O.A. Entry, Head Dips, and Distance as
dependent variables and dose and sex as independent variables was performed to assess
the overall effects of sex and drug treatment. One-way ANOVA and Dunnett’s post hoc
test, as described above, were subsequently performed within each sex group. The αvalue of significance was set at 0.05 for both ANOVA and Dunnett’s test. In all of the
figures, data were reported as means ± SEM. Asterisks represent significant differences
between the vehicle injected control group and the drug injected experimental groups as
assessed by post hoc Dunnett's comparisons, unless stated otherwise. *p < 0.05; **p <
0.01; ***p < 0.001.
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CHAPTER 4.

RESULTS

Systemic Injection of Selective GABAAR PAMs
To assess the differential roles of each GABAAR subtype in mediating BZinduced anxiolysis on the systemic level, subtype selective GABAAR PAMs were acutely
administered to both adult male C57BL/6J mice and several strains of point mutant mice
via systemic (i.p.) injection. The effects of the drugs on anxiety-like behaviors and motor
activities were assessed by the EPM test.
Systemic Injection of Zolpidem in WT C57BL/6J Mice
To assess the role α1-subtype GABAARs play in mediating anxiolysis, WT
C57BL/6J mice were given an i.p injection of the α1-subtype selective PAM, zolpidem,
at one of the following doses: 0.25mg/kg, 0.5mg/kg, 1mg/kg, or 2mg/kg. Mice were
tested on the EPM 30 min post-injection. The results are shown in Figure 4-1. One-way
ANOVA with dose as the independent variable revealed significant effects of zolpidem
on the dependent variables of % O.A. Entry, Head Dips, and Distance traveled on the
EPM, Fs(4, 35) > 4.15, ps < 0.01. No significant effect of zolpidem was found on the %
O.A. Time, F(4, 35) = 2.39, p = 0.07. Dunnett's comparisons revealed zolpidem exerted
anxiolytic-like effects as measured by significantly increased % O.A. Entry at 0.5mg/kg
and 1mg/kg doses (ps < 0.05). Zolpidem also exerted significant motor-inhibiting effects
as measured by significantly reduced distance traveled on the EPM at 1mg/kg and
2mg/kg doses (ps < 0.05). Further, zolpidem significantly reduced the Head Dips at
2mg/kg dose (p < 0.05), which was likely an effect correlated with motor inhibition. A
total of 40 mice were included in this experiment (Veh, n=12; 0.25mg/kg, n=8; 0.5mg/kg,
n=7; 1mg/kg, n=7; and 2mg/kg, n=6).
Systemic Injection of L-838417 in WT C57BL/6J Mice
To assess the that role α2-, α3-, (and α5-) subtype GABAARs play in mediating
anxiolysis, WT C57BL/6J mice were given an i.p. injection of the α2-, α3-, (and α5-)
subtype selective PAM, L-838417, at one of the following doses: 0.5mg/kg, or 2mg/kg.
Mice were tested on the EPM 30 min post-injection. The results are shown in Figure 4-2.
One-way ANOVA with dose as the independent variable revealed significant effects of
L-838417 on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and
Distance traveled on the EPM, Fs(2, 24) > 11.81, ps < 0.001. Dunnett's comparisons
revealed L-838417 exerted anxiolytic-like effects as measured by significantly increased
% O.A. Time and % O.A. Entry at 0.5mg/kg and 2mg/kg doses (ps < 0.001). L-838417
significantly increased the Head Dips at 0.5mg/kg and 2mg/kg doses (p < 0.001). Further,
L-838417 exerted significant motor-stimulating effects as measured by significantly
increased distance traveled on the EPM at 0.5mg/kg and 2mg/kg doses (ps < 0.01). A
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Figure 4-1.

Systemic Injection of Zolpidem in WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01; ***p < 0.001.
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Figure 4-2.

Systemic Injection of L-838417 in WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p <
0.01; ***p < 0.001.
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total of 27 mice were included in this experiment (Veh, n=12; 0.5mg/kg, n=7; and
2mg/kg, n=8).
Systemic Injection of L-838417 in α3(H126R) Mice
To assess the role α2- (and α5-) subtype GABAARs play in mediating anxiolysis,
α3(H126R) mice were given an i.p. injection of L-838417 at one of the following doses:
0.5mg/kg, 2mg/kg. Mice were tested on the EPM 30 min post-injection. The results are
shown in Figure 4-3. One-way ANOVA with dose as the independent variable revealed
no significant effect on the dependent variables of % O.A. Time, % O.A. Entry, Head
Dips, or Distance traveled, Fs(2, 22) < 3.28, p > 0.05. No post hoc Dunnett’s test was
performed. A total of 25 mice were included in this experiment (Veh, n=11; 0.5mg/kg,
n=7; and 2mg/kg, n=7).
Systemic Injection of TP003 in C57BL/6J Mice
To assess the role the α3-subtype GABAARs play in mediating anxiolysis,
C57BL/6J mice were given an i.p. injection of the α3-subtype selective PAM, TP003, at
one of the following doses: 0.5mg/kg, or 2mg/kg. Mice were tested on the EPM 30 min
post-injection. The results are shown in Figure 4-4. One-way ANOVA with dose as
independent variable revealed significant effects of TP003 on the dependent variables of
% O.A. Time, % O.A. Entry, Head Dips, and Distance traveled on the EPM, Fs(2, 23) >
5.54, ps < 0.05. Dunnett's comparisons revealed TP003 exerted anxiolytic-like effects as
measured by significantly increased % O.A. Time and % O.A. Entry at 0.5mg/kg and
2mg/kg doses (ps < 0.001). TP003 significantly increased the Head Dips at 0.5mg/kg and
2mg/kg doses (ps < 0.05). TP003 also exerted motor-stimulating effects as measured by
significantly increased distance traveled on the EPM at 0.5mg/kg dose (p < 0.01). A total
of 26 mice were included in this experiment (Veh, n=12; 0.5mg/kg, n=7; and 2mg/kg,
n=7).
Systemic Injection of Zolpidem in α1(H101R) Mice
To assess the selectivity of zolpidem towards α1-subtype GABAARs, α1(H101R)
mice were given an i.p. injection of zolpidem at one of the following doses: 1mg/kg, or
2mg/kg. As demonstrated previously, the dose 1mg/kg elicited anxiolytic-like effects in
C57BL/6J mice, while the dose 2mg/kg elicited motor-inhibiting effects. Mice were
tested on the EPM 30 min post-injection. The results are shown in Figure 4-5. One-way
ANOVA with dose as the independent variable revealed no significant effects of
zolpidem on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and
Distance traveled on the EPM, Fs(2, 19) < 2.07, ps > 0.1. This indicated that the
zolpidem lost its effects in α1(H101R) mice, and supported the hypothesis that the effects
of zolpidem seen in WT mice were indeed mediated by the α1-subtype GABAARs. A
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Figure 4-3.

Systemic Injection of L-838417 in α3(H126R) Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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Figure 4-4.

Systemic Injection of TP003 in WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01; ***p < 0.001.
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Figure 4-5.

Systemic Injection of Zolpidem in α1(H101R) Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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total of 22 mice were included in this experiment (Veh, n=7; 1mg/kg, n=8; and 2mg/kg,
n=7).
Systemic Injection of TP003 in α2(H101R) and α3(H126R) Mice
To assess the selectivity of TP003 towards α3-subtype GABAARs, α2(H101R)
and α3(H126R) mice were given an i.p. injection of TP003 at 2mg/kg dosage. As
demonstrated previously, this dose elicited prominent anxiolytic-like effects in WT
C57BL/6J mice. Mice were tested on the EPM 30 min post-injection. The results are
shown in Figure 4-6. Two-tailed t-test comparisons revealed significant effects of TP003
treatment on the dependent variables of % O.A. Time, % O.A. Entry, Head Dips, and
Distance traveled on the EPM in α2(H101R) mice, ps < 0.05. No significant effect of
TP003 was found on % O.A. Time, % O.A. Entry, or Head Dips in α3(H126R) mice.
However, a significant effect of TP003 on Distance traveled on the EPM was found (p <
0.05). Taken together, these data suggested that TP003 lost its anxiolytic-like effects in
α3(H126R) mice but retained its anxiolytic-like effects in α2(H101R), and indicated that
the anxiolytic-like effects were indeed mediated by α3-subtype GABAARs. Asterisks
represented significant difference between the vehicle injected control group and the drug
injected experimental group within each strain as assessed by two-tailed t-tests. A total of
35 mice were included in this experiment, [α2(H101R)-Veh, n=8; α2(H101R)-2mg/kg,
n=8; α3(H126R)-Veh, n=11; and α3(H126R)-2mg/kg, n=8]. *p < 0.05; **p < 0.01; NS:
non-significant.
Systemic Injection of Selective GABAAR PAMs – Other Parameters
Besides the parameters reported in the figures, descriptive statistics were obtained
for several other parameters, including the distance traveled on the open arm and closed
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center
Time) during the EPM experimentation, are summarized in Table 4-1.
Systemic Injection of Non-Selective CDP in Point Mutant Mice
To assess the effects of the non-selective BZ drug, CDP, on anxiety-like
behaviors, CDP was administered to both C57BL/6J mice and three strains of point
mutant mice α1(H101R), α2(H101R), and α3(H126R), via systemic (i.p.) injection. The
effects of the drug on anxiety-like behaviors and motor activities were assessed by the
EPM test. For this experiment, both males and females were used and were analyzed
separately.
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Figure 4-6.

Systemic Injection of TP003 in α2(H101R) and α3(H126R) Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represented significant difference between the vehicle
injected control group and the drug injected experimental group within each strain as
assessed by two-tailed t-test. *p < 0.05; **p < 0.01; NS: non-significant.
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Table 4-1.
Systemic Injection of Selective GABAAR PAMs – Descriptive
Statistics of Other Parameters
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Systemic Injection of CDP in WT C57BL/6J Mice
To assess the anxiolytic-like effects of CDP, C57BL/6J mice were given an i.p
injection of CDP at one of the following doses: 5mg/kg, or10mg/kg. Mice were tested on
the EPM 30 min post-injection. The results are shown in Figure 4-7 and Figure 4-8.
Two-way ANOVA with dose and sex as independent variables returned significant main
effects of dose on the dependent variables of % O.A. Time, % O.A. Entry, and Head Dip,
Fs(2,43) > 14.14, ps < 0.001. No significant effect of dose was detected on the dependent
variable of Distance, F(2,43) = 2.806, p = 0.072. No significant effect of sex or Sex ×
Dose interaction was detected, ps > 0.1.
For males, one-way ANOVA with dose as independent variable revealed
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry,
and Head Dips, Fs(2, 18) > 5.29, ps < 0.05. No significant effect of CDP was detected on
Distance traveled on the EPM, F(2,18) = 1.01, p > 0.05. Dunnett's comparisons revealed
CDP exerted anxiolytic-like effects as measured by significantly increased % O.A. Time
at 10mg/kg dose (p < 0.001) and % O.A. Entry at 5mg/kg and 10mg/kg doses (ps < 0.05).
CDP significantly increased the Head Dips at 10mg/kg dose (p < 0.01). A total of 21
mice were included in this experiment (Veh, n=8; 5mg/kg, n=6; and 10mg/kg, n=7).
For females, one-way ANOVA with dose as independent variable revealed
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry,
Head Dips, and Distance traveled on the EPM, Fs(2, 25) > 4.52, ps < 0.05. Dunnett's
comparisons revealed CDP exerted anxiolytic-like effects as measured by significantly
increased % O.A. Time, % O.A. Entry and Head Dips at 10mg/kg dose (ps < 0.001).
CDP also exerted motor-stimulating effects as measured by significantly increased
distance traveled on the EPM at 10mg/kg dose (p < 0.05). A total of 28 mice were
included in this experiment (Veh, n=9; 5mg/kg, n=6; and 10mg/kg, n=13).
Systemic Injection of CDP in α1(H101R) Mice
To assess the anxiolytic-like effects of CDP in mice expressing the BZ-insensitive
α1-subtype GABAARs, α1(H101R) mice were given an i.p. injection of CDP at one of the
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min postinjection. The results are shown in Figure 4-9 and Figure 4-10. Two-way ANOVA with
dose and sex as independent variables returned significant main effects of dose on the
dependent variables of % O.A. Time, % O.A. Entry, Head Dip, as well as Distance,
Fs(2,41) > 11.29, ps < 0.001. A significant main effect of sex on the dependent
variable % O.A. Time was also detected, F(1,41) = 8.00, p < 0.01. No significant Sex ×
Dose interaction was detected.
For males, one-way ANOVA with dose as independent variable revealed
significant effects of CDP on the dependent variables of % O.A. Entry, Head Dips, and
Distance traveled on the EPM, Fs(2, 20) > 7.36, ps < 0.01. No significant effect of CDP
was detected on the % O.A. Time, F(2,20) = 3.47, p = 0.0507. Dunnett's comparisons
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Figure 4-7.

Systemic Injection of CDP in Male WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
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Figure 4-8.

Systemic Injection of CDP in Female WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; ***p < 0.001.
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Figure 4-9.

Systemic Injection of CDP in Male α1(H101R) Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01; ***p < 0.001.
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Figure 4-10. Systemic Injection of CDP in Female α1(H101R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01; ***p < 0.001.
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revealed CDP exerted anxiolytic-like effects as measured by significantly increased %
O.A. Entry at 10mg/kg dose (p < 0.01). CDP also significantly increased the Head Dips
at 5mg/kg and 10mg/kg dose (ps < 0.05). A significant effect of CDP on motor activities
was detected at the 5mg/kg and 10mg/kg doses (ps < 0.05). A total of 23 mice were
included in this experiment (Veh, n=8; 5mg/kg, n=8; and 10mg/kg, n=7).
For females, one-way ANOVA with dose as independent variable revealed
significant effects of CDP on the dependent variables of % O.A. Time, % O.A. Entry,
and Head Dips, Fs(2, 21) > 6.15, ps < 0.01. No significant effect of CDP was detected on
the Distance traveled on the EPM, F(2,21) = 2.82, p > 0.05. Dunnett's comparisons
revealed CDP exerted anxiolytic-like effects as measured by significantly increased %
O.A. Time and % O.A. Entry at 5mg/kg and 10mg/kg doses (ps < 0.01). CDP also
significantly increased Head Dips at both 5mg/kg and 10mg/kg doses (ps < 0.05). A total
of 24 mice were included in this experiment (Veh, n=8; 5mg/kg, n=8; and10mg/kg, n=8).
Systemic Injection of CDP in α2(H101R) Mice
To assess the anxiolytic-like effects of CDP in mice with BZ-insensitive α2subtype GABAARs, α2(H101R) mice were given an i.p. injection of CDP at one of the
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min postinjection. The results are shown in Figure 4-11 and Figure 4-12. Two-way ANOVA
with dose and sex as independent variables returned significant main effects of dose on
the dependent variables of % O.A. Time, % O.A. Entry, and Distance, Fs(2,48) > 3.26, ps
< 0.05. Significant main effects of sex on the dependent variables of % O.A. Entry and
Head Dips were also detected, Fs(1,48) > 5.04, p < 0.05. A significant Sex × Dose
interaction was detected on the dependent variable of Distance, F(2,48) = 6.11, p < 0.01.
For males, one-way ANOVA with dose as independent variable revealed
significant effect of CDP on the dependent variable of Distance traveled, F(2,26) = 3.69,
p < 0.05. No significant effect was found on the dependent variables of % O.A. Time, %
O.A. Entry, and Head Dips, Fs(2, 26) < 2.32, ps > 0.1. Dunnett’s comparison revealed a
significant difference in Distance traveled at 5mg/kg dose when compared to the Vehicle
group (p < 0.05). A total of 29 mice were included in this experiment (Veh, n=11;
5mg/kg, n=10; and 10mg/kg, n=8).
For females, one-way ANOVA with dose as independent variable revealed no
significant effect of CDP on the dependent variables of % O.A. Time, % O.A. Entry and
Head Dips, Fs(2, 22) < 3.11, ps > 0.05. A significant effect of CDP on Distance traveled
on the EPM was found, F(2, 22) = 4.81, p < 0.05. However, post hoc Dunnett's
comparison returned no significant difference of the drug injected groups from the
vehicle injected group. A total of 25 mice were included in this experiment (Veh, n=10;
5mg/kg, n=8; and 10mg/kg, n=7).
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Figure 4-11. Systemic Injection of CDP in Male α2(H101R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05.
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Figure 4-12. Systemic Injection of CDP in Female α2(H101R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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Systemic Injection of CDP in α3(H126R) Mice
To assess the anxiolytic-like effects of CDP in mice with BZ-insensitive α3subtype GABAARs, α3(H126R) mice were given an i.p. injection of CDP at one of the
following doses: 5mg/kg, or 10mg/kg. Mice were tested on the EPM 30 min postinjection. The results are shown in Figure 4-13 and Figure 4-14. Two-way ANOVA
with dose and sex as independent variables returned significant main effects of dose on
the dependent variables of % O.A. Time and % O.A. Entry, Fs(2,43) > 4.60, ps < 0.05.
No significant effect of sex or Sex × Dose interaction was detected, ps > 0.05.
For males, one-way ANOVA with dose as independent variable revealed no
significant effect of CDP on the dependent variables of % O.A. Time, % O.A. Entry,
Head Dips, and Distance, Fs(2, 19) < 3.35, ps > 0.05. A total of 22 mice were included in
this experiment (Veh, n=8; 5mg/kg, n=6; and 10mg/kg, n=8).
For females, one-way ANOVA with dose as independent variable revealed
significant effects of CDP on the dependent variables of % O.A. Time, and % O.A.
Entry, Fs(2, 24) > 4.51, ps < 0.05. No significant effect was detected on the Head Dips
and Distance traveled on the EPM, Fs(2, 24) < 2.04, ps > 0.01. Dunnett's comparisons
revealed CDP exerted anxiolytic-like effects as measured by significantly increased %
O.A. Time and % O.A. Entry at 10mg/kg dose (ps < 0.05). A total of 27 mice were
included in this experiment (Veh, n=7; 5mg/kg, n=8; and 10mg/kg, n=12).
Systemic Injection of Non-Selective CDP – Other Parameters
Besides the parameters reported in the figures, descriptive statistics were obtained
for several other parameters, including the distance traveled on the open arm and closed
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center
Time) during the EPM experimentation, are summarized in Table 4-2.
Intra-BLA Microinjection of Selective GABAAR PAMs
To assess the differential role that GABAAR subtypes within the BLA play in
mediating BZ-induced anxiolysis, subtype selective GABAAR PAMs were administered
to both adult male C57BL/6J mice and α3(H126R) mice via intra-BLA microinjection.
The effects of the drugs on anxiety-like behaviors and motor activities were assessed by
the EPM.
Intra-BLA Microinjection of Zolpidem in WT C57BL/6J Mice
To assess the role α1-subtype GABAARs play in mediating anxiolysis within the
BLA, C57BL/6J mice were given bilateral intra-BLA microinjections of zolpidem at one
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Figure 4-13. Systemic Injection of CDP in Male α3(H126R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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Figure 4-14. Systemic Injection of CDP in Female α3(H126R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01.
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Table 4-2.
Systemic Injection of Non-Selective CDP – Descriptive Statistics of
Other Parameters
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of the following doses: 0.1µg/µL, 0.25µg/µL, or 0.5µg/µL in 0.3µL volume. Mice were
tested on the EPM 5-8 min post-injection. The results are shown in Figure 4-15. Oneway ANOVA with dose as independent variable revealed significant effects of zolpidem
microinjection on the dependent variables of % O.A. Time, and % O.A. Entry, Fs(3, 39)
> 3.43, ps < 0.05. No significant effect on Head Dips and Distance traveled was detected,
Fs(3, 39) < 2.07, ps > 0.1. Dunnett's comparisons revealed zolpidem exerted anxiolyticlike effects as measured by significantly increased % O.A. Time at 0.1µg/µL dose (p <
0.05). However, post hoc Dunnett’s test revealed no significant difference in the % O.A.
Entry between the drug injected groups and the vehicle injected group. A total of 43 mice
were included in this experiment (Veh, n=14; 0.1µg/µL, n=10; 0.25µg/µL, n=10; and
0.5µg/µL, n=9).
Intra-BLA Microinjection of L-838417 in α3(H126R) Mice
To assess the role the α2- (and α5-) subtype GABAARs play in mediating
anxiolysis within the BLA, α3(H126R) mice were given bilateral intra-BLA
microinjection of L-838417 at one of the following doses: 0.25µg/µL, or 0.5µg/µL in
0.3µL volume. Mice were tested on the EPM 5-8 min post-injection. The results are
shown in Figure 4-16. One-way ANOVA with dose as the independent variable revealed
a significant effect of L-838417 microinjection in α3(H126R) mice on the dependent
variables of Head Dips, F(2, 21) = 3.95, p < 0.05. No significant effect was detected on
% O.A. Time, % O.A. Entry or Distance traveled, Fs(2, 21) < 2.96, p > 0.05. Dunnett's
comparisons revealed L-838417 exerted anxiolytic-like effects as measured by
significantly increased Head Dips at 0.5µg/µL dose (p < 0.05). A total of 24 mice were
included in this experiment (Veh, n=10; 0.25µg/µL, n=7; and 0.5µg/µL, n=7).
Intra-BLA Microinjection of TP003 in WT C57BL/6J Mice
To assess the role the α3-subtype GABAARs play in mediating anxiolysis within
the BLA, WT C57BL/6J mice were given bilateral intra-BLA microinjections of TP003
at one of the following dose: 0.1µg/µL, 0.25µg/µL, or 0.5µg/µL in 0.3µL volume. Mice
were tested on the EPM 5-8 min post-injection. The results are shown in Figure 4-17.
One-way ANOVA with dose as independent variable revealed significant effect of TP003
microinjection in WT mice on the dependent variable of % O.A. Time, F(3, 37) = 5.11, p
< 0.05. No significant effect on % O.A. Entry, Head Dips, or Distance traveled was
detected, Fs(3, 37) < 2.34, p > 0.05. Dunnett's comparisons revealed TP003 exerted
anxiolytic-like effects as measured by significantly increased % O.A. Time at 0.25µg/µL
and 0.5µg/µL dose (ps < 0.01). A total of 41 mice were included in this experiment (Veh,
n=14; 0.1µg/µL, n=9; 0.25µg/µL, n=8; and 0.5µg/µL, n=10).
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Figure 4-15.

Intra-BLA Microinjection of Zolpidem in WT C57BL/6J Mice

Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p <
0.01.
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Figure 4-16. Intra-BLA Microinjection of L-838417 in α3(H126R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05.
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Figure 4-17. Intra-BLA Microinjection of TP003 in WT C57BL/6J Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. **p <
0.01.
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Intra-BLA Microinjection of Subtype Selective GABAAR PAMs – Other
Parameters
Besides the parameters reported in the figures, descriptive statistics were obtained
for several other parameters, including the distance traveled on the open arm and closed
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center
Time) during the EPM experimentation, are summarized in Table 4-3.
Intra-BLA Microinjection of Non-Selective CDP in Point Mutant Mice
To assess the effects of a non-selective BZ drug, CDP, on anxiety-like behaviors
within the BLA, CDP was administered to both C57BL/6J mice and three strains of point
mutant mice, α1(H101R), α2(H101R), and α3(H126R), via intra-BLA microinjection.
The effects of the drugs on anxiety-like behaviors and motor activities were assessed by
the EPM.
Intra-BLA Microinjection of CDP in WT C57BL/6J Mice
To assess the anxiolytic-like effects of CDP within the BLA, WT C57BL/6J mice
were given bilateral intra-BLA microinjections of CDP at one of the following doses:
10µg/µL, or 20 µg/µL in 0.3uL volume. Mice were tested on the EPM 5-8 min postinjection. The results are shown in Figure 4-18. One-way ANOVA with dose as
independent variable revealed no significant effect of CDP microinjection on the
dependent variables of % O.A. Time, % O.A. Entry, Head Dips, or Distance traveled,
Fs(2, 21) < 1.34, p > 0.1. A total of 24 mice were included in this experiment (Veh, n=9;
10µg/µL, n=6; and 20µg/µL, n=9).
Intra-BLA Microinjection of CDP in α1(H101R) Mice
To assess the anxiolytic-like effects of CDP within the BLA in mice expressing
the BZ-insensitive α1-subtype, α1(H101R) mice were given bilateral intra-BLA
microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in
Figure 4-19. One-way ANOVA with dose as independent variable revealed no
significant effect of CDP microinjection on the dependent variables of % O.A. Time, %
O.A. Entry, Head Dips, or Distance traveled, Fs(2, 19) < 0.74, p > 0.1. A total of 22 mice
were included in this experiment (Veh, n=8; 10µg/µL, n=7; 20µg/µL, n=7).
Intra-BLA Microinjection of CDP in α2(H101R) Mice
To assess the anxiolytic-like effects of CDP within the BLA in mice expressing
the BZ-insensitive α2-subtype, α2(H101R) mice were given bilateral intra-BLA
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Table 4-3.
Intra-BLA Microinjection of Subtype Selective GABAAR PAMs –
Descriptive Statistics of Other Parameters
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Figure 4-18. Intra-BLA Microinjection of CDP in WT C57BL/6J Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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Figure 4-19. Intra-BLA Microinjection of CDP in α1(H101R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in
Figure 4-20. One-way ANOVA with dose as independent variable revealed no
significant effect of CDP microinjection on the dependent variables of % O.A. Time, %
O.A. Entry, Head Dips and Distance traveled on the EPM, Fs(2, 16) < 1.91, ps > 0.1. A
total of 19 mice were included in this experiment (Veh, n=7; 10µg/µL, n=6; and
20µg/µL, n=6).
Intra-BLA Microinjection of CDP to α3(H126R) Mice
To assess the anxiolytic-like effects of CDP within the BLA in mice expressing
the BZ-insensitive α3-subtype, α3(H126R) mice were given bilateral intra-BLA
microinjections of CDP at one of the following doses: 10µg/µL, or 20 µg/µL in 0.3uL
volume. Mice were tested on the EPM 5-8 min post-injection. The results are shown in
Figure 4-21. One-way ANOVA with dose as independent variable revealed significant
effects of CDP microinjection on the dependent variables of Head Dips, and Distance
traveled on the EPM, Fs(2, 20) > 4.11, ps < 0.05. No significant effect was found on the
dependent variables of % O.A. Time and % O.A. Entry. Dunnett’s test revealed that CDP
exerted significant anxiolytic-like and motor-stimulating effects as measured by
significantly increased Head Dips and Distance traveled on the EPM at 20 µg/µL dose
when compared to vehicle group (ps < 0.05). A total of 23 mice were included in this
experiment (Veh, n=9; 10µg/µL, n=5; and 20µg/µL, n=9).
Intra-BLA Microinjection of Non-Selective CDP – Other Parameters
Besides the parameters reported in the figures, descriptive statistics were obtained
for several other parameters, including the distance traveled on the open arm and closed
arm, respectively (O.A. Distance, C.A. Distance), time and entry to the distal open arm
(D.O.A. Time, D.O.A. Entry), as well as the time animal spent in the center zone (Center
Time) during the EPM experimentation, are summarized in Table 4-4.
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Figure 4-20. Intra-BLA Microinjection of CDP in α2(H101R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM.
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Figure 4-21. Intra-BLA Microinjection of CDP in α3(H126R) Mice
Anxiety-like and locomotor behaviors following drug treatment as assessed by elevated
plus maze (EPM) test. (A): percentage of time spent on the open arm (% O.A. Time). (B):
percentage of entry to the open arm (% O.A. Entry). (C): counts of incidences where the
animal extended its head over the edge of the open arm (Head Dips). (D): total distance
traveled on the EPM. Asterisks represent significant differences between the vehicle
injected control group and the drug injected experimental groups as assessed by ANOVA
followed by post hoc Dunnett's comparisons against vehicle (Veh) injected group. *p <
0.05; **p < 0.01.
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Table 4-4.
Intra-BLA Microinjection of Non-Selective CDP – Descriptive
Statistics of Other Parameters
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CHAPTER 5.

DISCUSSION

Summary of Findings
The goal of this study was to further discern the contributions of different αsubtype GABAARs to BZ-induced anxiolysis based on current existing knowledge. To
accomplish this, we examined the anxiolytic-like effects of various subtype selective and
non-selective GABAAR PAMs given to WT C57BL/6J mice and point mutant mice that
express BZ-insensitive α1-, α2-, or α3-subtype GABAARs. Because the BLA is known as
a brain region that plays a pivotal role in mediating anxiety-like effects of BZs (M. Davis,
2000; Green & Vale, 1992; Heldt & Ressler, 2006; Pesold & Treit, 1995; Sanders &
Shekhar, 1995), we also examined anxiolytic-like effects of intra-BLA microinjections of
GABAAR PAMs in WT mice as well as point mutant mice.
The Effects of Systemic Injection of Selective GABAAR PAMs
In the experiment using systemic injection of selective drugs, we found that
selective positive modulation of α1-subtype GABAARs by zolpidem produced mild
anxiolytic-like effects in WT mice. The dose response relationships were in the form of
inverted-U shape functions for the measurements of anxiety-like behaviors. Specifically,
an increase of % O.A. Entry could be observed at doses of 0.5mg/kg and 1mg/kg.
Systemic administration of zolpidem also produced a dose-dependent inhibition of motor
activities, and resulted in pronounced motor-inhibiting effects at higher does (1mg/kg and
2mg/kg). This is in sharp contrast to the result obtained from α1(H101R) mice, where no
effect on neither anxiety-like measurements nor motor activity was observed, suggesting
the effects seen in WT mice were indeed mediated by the α1-subtype GABAARs.
Selective positive modulation of α2-, α3-, (and α5-) subtype GABAARs by
systemic injection of L-838417 (0.5mg/kg and 2mg/kg) produced profound anxiolyticlike effects in WT mice as indicated by increases in % O.A. Time, % O.A. Entry and
Head Dips. These effects were accompanied by motor-stimulating effects at both doses
tested. On the contrary, selective positive modulation of α2-, (and α5-) subtype
GABAARs by systemic injection of L-838417 to α3(H126R) mice elicited no statistically
significant effects on the main measurements of anxiety-like behaviors or motor activity,
suggesting that the α3-subtype GABAARs are responsible for mediating a significant
portion of the effects of L-838417 in the EPM paradigm. These findings were in line with
a previous study showing the anxiolytic-like effects of L-838417 were left intact in
α2(H101R) mice in a conditioned emotional response test (Morris et al., 2006), signifying
the contribution of α3-subtype GABAARs. However, one-way ANOVA of the
measurements related to the animal’s activity on the distal open arm (D.O.A.), such as
D.O.A. Time and D.O.A. Entry, detected significant anxiolytic-like effects of L-838417
in α3(H126R) mice, Fs(2, 22) > 4.03, ps < 0.05. Post hoc Dunnett’s tests revealed the
effects were only seen at the high dose of 2mg/kg, ps < 0.05. This suggested that the
involvement of α2-subtype in mediating L-838417 induced anxiolysis should not be
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overlooked. Taken together, we conclude that both α3-, and to a lesser extent, α2-subtype
GABAARs contribute to the anxiolytic-like effects of L-838417 at doses tested.
Selective positive modulation of α3-subtype GABAARs by systemic injection of
TP003 (0.5mg/kg and 2mg/kg) produced profound anxiolytic-like effects in WT mice at
both doses tested. Motor-stimulating effects at 0.5mg/kg dose were also observed.
Importantly, the anxiolytic-like effects of systemic TP003 injection were completely
abolished in α3(H126R) mice. In contrast, TP003 retained its anxiolytic-like effects in
α2(H101R) mice, suggesting the anxiolytic-like effects of TP003 were indeed mediated
by α3-, but not α2-subtype GABAARs. Interestingly, TP003 exerted motor-stimulating
effects in α3(H126R) mice, suggesting that (i) the motor-stimulating effects of TP003
were not mediated entirely by the α3-subtype GABAARs, and (ii) the anxiolytic-like
effects of TP003 in WT mice were not simply due to heightened locomotor activities.
Together, our results suggested that (i) systemic positive modulation of the α1subtype GABAARs exerted anxiolytic-like effects at certain doses, however, the
“therapeutic window” was narrow and the dose for anxiolysis overlapped with the dose
for motor-impairment; (ii) systemic positive modulation of the α2-, α3-, (and α5-)
subtype GABAARs exerted anxiolytic-like effects and motor-stimulating effects, and
such effects were weakened in α3(H126R) mice; and (iii) systemic positive modulation
of the α3-subtype GABAARs exerted anxiolytic-like effects which were accompanied by
motor-stimulating effects, although the exact molecular substrates for the motorstimulating effects remained unclear.
The Effects of Systemic Injection of the Non-Selective CDP
To extend a previous study (K. S. Smith et al., 2012) that investigated the effect
of CDP in male point mutant mice and to explore the potential sex differences in animals’
response to BZ-induced anxiolysis, both males and females are used in this experiment.
In the experiment of systemic injection of non-selective CDP, we found that although
males and females generally showed little differences in terms of their response to drug
treatment, some discrepancies do exist. Systemic injection of CDP elicited significant
anxiolytic-like effects in both male and female WT C57BL/6J mice as well as α1(H101R)
mice. Systemic injection of CDP produced no anxiolytic-like effects in male α2(H101R)
mice, or in female α2(H101R) mice. Interestingly, in our experiment, systemic injection
of CDP produced no statistically significant anxiolytic-like effects in male α3(H126R)
mice, although in female α3(H126R) mice the anxiolytic-like effects were present. These
results indicated that the anxiolytic-like effects of systemic CDP injection were left intact
when α1-subtype GABAARs were mutated, however, the anxiolytic-like effects were
weakened when α2-, as well as α3-subtype GABAARs were mutated, suggesting that (i)
the α1-subtype GABAARs are dispensable for BZ-induced anxiolysis, and (ii) both the
α2- and α3-subtype GABAARs are needed for BZ to exert its full effects in inducing
anxiolysis.
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The Effects of Intra-BLA Microinjection of Selective GABAAR PAMs
In the experiment with intra-BLA microinjection of selective drugs, we found that
selective positive modulation of α1-subtype GABAARs by zolpidem within the BLA
produced an anxiolytic-like effect at 0.1μg/μL dose, but not other doses tested. Similar to
the systemic injection result, the dose response curves were in the form of inverted-U
shape functions for the measurements of anxiety-like behaviors, although no motor
inhibition or stimulation was observed. Selective positive modulation of α2-, (and α5-)
subtype GABAARs via intra-BLA microinjection of L-838417 in α3(H126R) mice
produced anxiolytic-like effects at 0.5μg/μL dose with no significant effect on motor
activity. Selective positive modulation of α3-subtype GABAARs via intra-BLA
microinjection of TP003 produced anxiolytic-like effects at 0.25μg/μL and 0.5μg/μL
doses, and again, the impact on motor activity was minimal. Together, our results
suggested that (i) intra-BLA microinjection of subtype selective drugs produced similar
behavioral outcomes when compared to systemic injections in terms of anxiety-like
behaviors; (ii) intra-BLA microinjection of subtype selective drugs generally produced
little impact on motor activities; and (iii) BLA is critically involved in mediating the
anxiolytic-like effects but not the locomotor effects of the subtype selective drugs.
The Effects of Intra-BLA Microinjection of Non-Selective CDP
In the experiment with intra-BLA microinjection of the non-selective CDP, our
findings were unanticipated in light of previous studies that showed intra-BLA
microinjection of midazolam and CDP produces anxiolytic-like effects as measured by
the EPM and open field test (McNamara & Skeleton, 1993; Menard & Treit, 1999;
Pesold & Treit, 1995). Unexpectedly, no statistically significant anxiolytic-like effect
were found when CDP was microinjected to the BLA of WT, α1(H101R), or α2(H101R)
mice. Anxiolytic-like effects could be observed when CDP was microinjected to the BLA
of α3(H126R) mice, and were accompanied by an unexpected motor-stimulating effects,
suggesting that the BLA is involved in certain aspects of the anxiolytic-like and motorstimulating effects of the non-selective BZ drug CDP.
Interpretation of Results
Although the EPM is a standardized behavioral paradigm to assess anxiety-like
behaviors in rodents, the actual design of the EPM apparatus and the testing conditions
are far from uniform across different laboratories. Variations could arise from a number
of discrepancies such as the opacity of the maze walls, the size of the testing room, and
the illumination condition (Violle, Balandras, Le Roux, Desor, & Schroeder, 2009). This
inevitably makes direct comparison between results obtained from studies using different
testing conditions somewhat problematic. In this study, we used the same EPM apparatus
in a standard behavioral testing room with controlled lighting condition to minimize test
variations, which allowed reliable comparison of test scores across different experiments.
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The results obtained in the experiments with systemic injection of selective drugs
were generally in line with previous studies. Systemic positive modulation of the α1subtype GABAARs by zolpidem exerted mild anxiolytic-like effects at certain doses.
However, the “therapeutic window” was narrow and the dose for anxiolysis overlapped
with the dose for motor-inhibiting effects. This is in line with a previous study that
reported similar findings in rats (Griebel, Sanger, & Perrault, 1996), and is in keeping
with another study that suggested the involvement of α1-subtype in anxiety (Belzung et
al., 2000). However, from a pharmacological point of view, the narrow therapeutic
window would severely limit the application of zolpidem as a systemic anxiolytic drug.
Systemic positive modulation of the α2-subtype GABAARs by injection of L-838417 in
α3(H126R) mice exerted minimal anxiolytic-like effects at doses tested as revealed by
non-significant statistical results on the main measurements of anxiety-like behaviors,
which appeared much weaker than the effects of L-838417 found in WT mice. However,
parameters related to the animal’s activity on the D.O.A. revealed some residue
anxiolytic-like effects of L-838417 in α3(H126R) mice. This suggests that the α2-subtype
GABAARs, previously thought to play a pivotal role in mediating BZ-induced anxiolysis
(Low et al., 2000; K. S. Smith et al., 2012), were in fact partially involved in mediating
the anxiolytic-like effects elicited by L-838417 at doses tested. Systemic positive
modulation of the α3-subtype GABAARs by injection of TP003 in WT mice exerted
anxiolytic-like effects. This is also in keeping with the previous finding (Atack et al.,
2005; Dias et al., 2005; Fischer et al., 2011) that suggested the involvement of α3subtype in anxiety. Our data also revealed a motor-stimulating effects induced by
systemic injection of TP003. However, systemic TP003 treatment retained its motorstimulating effects in α3(H126R) mice, whereas the anxiolytic-like effects were
completely abolished. This suggests the motor-stimulating effect of TP003 might not be
entirely mediated by the α3-subtype GABAARs.
In line with previous studies (K. S. Smith et al., 2012), systemic positive
modulation of the α1-, α2-, α3-, (and α5-) subtype GABAARs by injection of CDP in WT
mice exerted anxiolytic-like effects in males. Similar effects were also observed in
female WTs. The anxiolytic-like effects were preserved in both male and female
α1(H101R) mice. Of note, for female subjects, the 5mg/kg dose elicited no significant
anxiolytic-like effects in WTs, whereas the same dose elicited prominent anxiolytic-like
effects in α1(H101R) mice, suggesting the anxiolytic-like effects of CDP was not only
preserved, but also potentiated in female mice lacking BZ-sensitive α1-subtype
GABAARs. Expectedly, both male and female α2(H101R) mice were generally
insensitive towards the anxiolytic-like effects of systemic CDP injection. Surprisingly,
systemic injection of CDP elicited no significant anxiolytic-like effects in male
α3(H126R) mice, which was in contrast with a previous report (K. S. Smith et al., 2012).
On the other hand, female α3(H126R) mice remained sensitive toward CDP induced
anxiolysis. To sum up, (i) for males, the anxiolytic-like effects of BZ were unaffected in
α1(H101R) mice, and reduced in α2(H101R) as well as α3(H126R) mice, suggesting both
α2- and α3-subtypes were crucially involved, and α1-subtype GABAARs were
dispensable, (ii) for females, the anxiolytic-like effects of BZ were potentiated in
α1(H101R) mice, reduced in α2(H101R) mice and preserved in α3(H126R) mice,
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suggesting that only α2-subtype GABAARs were crucially involved, while α1- and α3subtypes were dispensable.
The sex differences observed suggested that female mice were generally more
resilient in terms of their sensitivity towards BZ-induced anxiolysis when a particular αsubtype is mutated. Sex differences in GABAergic signaling were supported by various
studies in human as well as in animals. For example, a previous study showed that the
availability of BZ-sensitive GABAAR in women was higher when compared to men
(Esterlis et al., 2013). In rodents, one study showed that the expressions of α1- and α3subtype GABAARs in the anterior substantia nigra pars reticulata were higher in females
than males at postnatal day 5 (Chudomel, Herman, Nair, Moshe, & Galanopoulou, 2009).
However, other studies revealed no drastic sex differences in the expression of α1-, α2-,
or α5-subunit (A. M. Davis, Penschuck, Fritschy, & McCarthy, 2000; Nett, Jorge-Rivera,
Myers, Clark, & Henderson, 1999). These findings, although ambiguous, offered a
possible rationale that sex differences in GABAAR expression level could explain why
female mice might be more likely to retain sensitivity to BZ-induced anxiolysis when a
particular α-subtype was rendered BZ-insensitive than their male counterparts. Future
experiments addressing the sex-differences of GABAAR expression in the BLA and the
response towards BZ-induced anxiolysis in rodents would be of great interest.
Currently, the effect of intra-BLA microinjection of selective drugs is poorly
understood. Our results revealed that selective intra-BLA positive modulation of α1-, α2-,
or α3-subtype GABAARs produced similar anxiolytic-like behavioral outcomes when
compared to systemic positive modulation. This suggested that BLA is indeed a critical
brain region which is sufficient to mediate the anxiolytic-like effects, but not the motorinhibiting or stimulating effects of the subtype selective GABAAR PAMs.
The result obtained from the intra-BLA microinjection of CDP experiment was
somewhat difficult to interpret. CDP elicited no pronounced anxiolytic-like effects in
WT, α1(H101R) or α2(H101R) mice, when administered directly to the BLA. This is in
contrast to previous studies that showed intra-BLA microinjection of CDP and
midazolam elicited anxiolytic-like effects in the EPM test or open field test in rodents
(McNamara & Skeleton, 1993; Menard & Treit, 1999; Pesold & Treit, 1995). The
observed phenomena might be sensitive to the test conditions, i.e., due to the lighting
condition and the particular construction of the EPM used in our experiment that had
transparent plexiglass walls around the closed arm, rather than opaque or wooden ones
used in many other studies. These particular factors were known to affect the animal’s
behavior on the EPM (Violle et al., 2009). Another possible explanation is that since
GABAARs are known to be differentially expressed on different populations of
GABAergic interneurons (Baude, Bleasdale, Dalezios, Somogyi, & Klausberger, 2007;
Milenkovic et al., 2013), the augmentation effects of PAMs, including CDP, on the
GABAAR may not be restricted to the projection neurons. It is possible that application of
CDP locally would cause inhibition of certain population of GABAergic interneurons,
and subsequently result in reduced GABA release from those neurons which might
further cancel out the potentiation of the inhibitory effects exerted by CDP on the
projection neurons. Molecular and functional characterization of the GABAARs
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expressed on the GABAergic interneurons within the BLA would be of great value to
help better understand the properties of the GABAergic microcircuitries and their
functions in the context of fear and anxiety. A third possibility is that under certain
circumstances, GABA signaling might actually be excitatory rather than inhibitory. A
recent study suggested that a subpopulation of parvalbumin positive interneurons could
synchronize the activity of a group of pyramidal neurons via GABAergic excitation
within the BLA (Spampanato, Sullivan, Perumal, & Sah, 2016). It is thus also likely that
BZ-induced augmentation of GABAARs might increase the synchronizing effect of the
parvalbumin positive interneurons and subsequently enhance the BLA net output. Further
studies that focus on addressing the alteration of intra-BLA GABAergic microcircuitries
under the influence of CDP will benefit the understanding of the paradoxical effects seen
here in the intra-BLA CDP microinjection experiment.
Limitations of Experimental Design and Results
As mentioned above, the EPM test is a locomotion-dependent behavioral
paradigm and the measurements of anxiety should be examined with care when a motorinhibiting or stimulating effects are present (Reynolds et al., 2001). However, the use of
entry ratios (% O.A. Entry), rather than the raw numbers of O.A. entry, should help to at
least reduce the bias introduced by locomotion differences amongst different groups.
Future experiments employing locomotion-independent anxiety tests, such as stressinduced hyperthermia, would be beneficial for this matter.
In this study, only one brain region, i.e. the BLA, is investigated. As previously
mentioned, the BNST and hippocampus are two other main brain regions known to play a
role in anxiety-like behaviors (Engin & Treit, 2007b; Gafford et al., 2012). Future studies
investigating the anxiolytic-like effects of intra-BNST and intra-hippocampus
microinjection of selective and non-selective GABAAR PAMs in WT and point mutant
mice would be of great importance in pinpointing the regional specific roles the
GABAAR α-subtypes play in mediating BZ-induced anxiolysis.
Conclusion and Clinical Significance
In an attempt to unify the current debate concerning “which GABAAR α-subtype
contributes to BZ-induced anxiolysis”, this study incorporates both subtype selective
GABAAR PAM and α-subunit point mutant mice to finely dissect the functional roles
played by α1-, α2-, and α3-subtype GABAARs in mediating anxiety-like behaviors and
anxiolysis-like effects. In general, our findings support the conclusion that both α1-, α2-,
and α3-subtype GABAARs are involved in mediating anxiety-like behaviors. However,
subtle differences do exist. Positive modulation of α1-subtype GABAARs exerts
anxiolytic-like effects with a narrow therapeutic window that overlaps with the dose for
motor-inhibiting effects. In contrast, positive modulation of α2-, α3- (and α5-) subtype
GABAARs exerts significant anxiolytic-like and motor-stimulating effects. These effects
are weakened in the absence of BZ-sensitive α3-subtypes. Positive modulation of the α3-
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subtype GABAARs exerts anxiolytic-like effects that are accompanied by significant
motor-stimulating effects. Lack of either BZ-sensitive α2-, or α3-subtype GABAARs
weakened the anxiolytic-like effects of CDP in a sex-dependent manner. Together, our
findings sufficiently addressed the currently debatable view of the role played by the α3subtype GABAARs in BZ-induced anxiolysis.
We have also extended the current understanding of the differential roles played
by α1-, α2-, and α3-subtype GABAARs on anxiety-like behaviors from the systemic level
to a specific brain area, the BLA. Our data clearly indicates that the anxiolytic-like effects
of selective intra-BLA positive modulation of α1-, α2-, and α3-subtype GABAARs are
largely similar to the systemic positive modulation, in absence of the impact on motor
activities. The non-selective positive modulation of GABAARs in the BLA results in
minimal, unclear effects on anxiety measures, which might be explained by a complex
inhibition / disinhibition balance between the GABAARs expressed on the projection
neurons versus the GABAARs expressed on the inhibitory interneurons under the
influence of non-selective BZs within the BLA.
Our results suggest that α3- and/or α2-subtype selective GABAAR PAMs, such as
TP003, could be prime candidates for developing selective anxiolytic drugs. The motorstimulating effects found in systemic TP003 treatment should be further investigated to
identify the exact molecular substrate mediating such effects. Our results also suggest
that novel α2-subtype selective GABAAR PAMs would be of great value for both
developing anxiolytic drugs, and for advancing the investigation of the differential
functional roles played by different GABAAR α-subtypes in the brain.
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